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Determine the presence of a brain condition associated with centralized pain in a 
subject suffering from pain by taking measures of the subject's brain either by direct 
assessment techniques such as neuroimaging or by indirect assessment such as analysis 
of other biological measures 
Diagnose one or more brain conditions associated with centralized pain by diagnosing 
the presence of one or more centralized pain-associated brain conditions that area 
result of central sensitivity or abnormal network connectivity involved in pain processing 
Locate at least one area of abnormal brain measure associated with an abnormal brain 
condition producing the centralized pain, or at least one target region of the subject's 
brain where a brain condition involved in producing centralized pain originates 
Apply to tissues corresponding to the at least one area of abnormal brain measure or 
the at least one target region, a cortical stimulation signal, such as a signal that 
comprises waveforms configured to minimize tissue impedance such as an AMPWM 
signal, configured to alter the one or more brain conditions in such a way as to alleviate 
the centralized pain 
End 
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Determine the presence of centralized pain using a brain response test comprising a 
neuroimaging test such as an EEG test for a period of time before application of any one or 
more sensory stimulations that might cause one or more brain responses 
Perform one or more additional neuroimaging tests for a period of time during the 
application of one or more noxious or non-noxious, pain inducing or non-pain inducing 
sensory stimulations such as a tender point test, application of mechanical pressure on any 
part of the body, application of other forms of mechanical stimulation to any part of the 
body, application of an electrical stimulus, application of a heat-producing stimulus, in vivo 
or in vitro introduction of a chemical agent, mechanical brushing, controlled physical 
movements made by the subject, and/or forms of mental processing such as cognitive 
exercises; any of which may be conceived to cause one or more brain responses 
Repeat one or more sensory stimulations and one or more neuroimaging tests over a 
period of time in such a way as to produce and record multiple brain responses 
Perform one or more additional neuroimaging tests for a period of time after the 
application of the one or more seriory stimulations 
Create a brain response test record that includes quantified parameters and statistics of 
neuroimaging tests, and those parameters aSSociated with the one or more sensory 
stimulations including parameters such as location of mechanical pressure, amount of 
mechanical pressure, parameters of other forms of mechanical stimuli, parameters of 
forms of electrical stimuli, parameters of forms of heat stimuli, parameters of an 
introduced chemical agent, parameters of brushstrokes, and/or parameters of a mental 
exercise; and such quantified parameters including those occurring at or near the time the 
subject reports a painful sensation 
Determine the presence of centralized pain, either with or without augmenting physical 
assessment, by assessing a brain response test record for changes in brain response to 
sensory stimulations over time to discover one or more brain conditions associated with 
central sensitivity or abnormal brain network connectivity following the application of the 
one or more sensory stimulations 
Diagnose centralized pain based on analyzing findings from one or more brain response 
tests to determine one or more brain measures, such as those associated with central 
Sensitivity or abnormal brain network connectivity associated with pain processing, to 
Support a diagnosis of the presence of one or more brain conditions associated with 
centralized pain, either with or without a statistical comparison for likeness or deviations 
between any one or more of the subject's brain response test measures and databases of 
like brain response test measures of either healthy normal individuals, individuals suffering 
from pain that is not Centralized pain, or individuals suffering from centralized pain 
End 
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Determine the presence of centralized pain by performing a brain response test 
comprising one or more applications of one or more sensory stimulations and an EEG 
test following each such application, and producing a resulting EEG data record that 
includes brain response test EEG records 
Extract non-EEG signals from EEG data so that each EEG record provides a period of 
clean EEG data that is sufficient to perform an EEG analysis and does not include any 
EEG data acquired during the application of any one or more sensory stimulations 
Mathematically analyze clean brain response test EEG records by using voltage analysis, 
current analysis, voltage and current analysis, frequency spectrum analysis using Fast 
Fourier Transform (FFT) analysis, frequency spectrum analysis using a wavelet analysis 
method, frequency spectrum analysis using absolute power analysis method, frequency 
spectrum analysis using relative power analysis method, frequency spectrum analysis 
using phase analysis method, frequency spectrum analysis using coherence analysis 
method, frequency spectrum analysis using amplitude Symmetry analysis method, 
phase analysis, various forms of network analysis, and/or source localization of 
electrical activity in the brain using inverse EEG computation analysis 
Statistically compare brain response test EEG records to EEG records taken from either 
healthy normal individuals or individuals that are suffering from pain that is not 
centralized pain 
Make a determination of the presence of centralized pain by determining brain response 
test EEG abnormalities that are consistent with subjects suffering from centralized pain and 
that include abnormal levels of EEG power, abnormal levels of coherence between at least 
two EEG sites, abnormal levels of phase shift between at least two EEG sites, and/or 
abnormal levels of EEG relative power in particular regions of the brain 
End 
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Execute a brain response test on a subject 
Obtain brain measures associated with centralized pain in the subject by analyzing 
findings from the brain response testing 
Predict symptom severity in individuals having centralized pain by correlating the brain 
measures to measures of Symptom severity 
End 
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- Execute a brain response test on a subject 
Obtain brain measures associated with centralized pain in the subject by analyzing findings 
from the brain response testing 
Determine the effect of therapeutic intervention in alleviating symptoms of centralized pain by 
correlating the brain measures to measures of the effect of therapeutic intervention 
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Execute a brain response test on a subject 
Obtain brain measures associated with centralized pain in the subject by analyzing 
findings from the brain response testing 
Determine points for application of cortical stimulation using analysis of findings from 
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Diagnose one or more brain conditions associated with centralized pain such as that 
arising from central sensitivity or from abnormal network connectivity, by assessing the 
brain of a subject either by direct assessment techniques such as neuroimaging, or by 
indirect assessment such as analysis of other biological measures 
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analyses to like parameters of the analyses of the subject's brain response test measures done before 
the period of therapeutic intervention was started 
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Acquire brain response test method data at a first location 
Transfer the data via electronic means, such as a local area network or the internet, to a 
second location for one or more analyses and statistical comparisons 
Perform one or more brain response test method analyses and statistical comparisons 
at the second location 
Determine cortical stimulation signal parameters at the second location 
Use brain response test method data obtained at the first location and transferred to 
the second location, to increase the size of databases of individuals known to be 
suffering from centralized pain, or of individuals known to be suffering from pain that is 
not centralized pain, or of healthy normal individuals 
Transfer brain response test method analyses and statistical comparisons findings via 
electronic means, such as a local area network or the internet, from the second location 
to the first location 
Transfer cortical stimulation signal parameters determined at the second location to an apparatus 
at the first location via electronic means, such as a local area network or the internet 
End 
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Collect brain measures associated with one or more abnormal brain conditions 
associated with centralized pain, such as measures from a brain response test 
comprising an EEG test, during a time at or near the time of a therapeutic intervention 
such as application of a Cortical stimulation signal 
Determine measures and statistics associated with the brain measures, such as 
measures and statistics of EEG data taken from two or more scalp locations to 
determine brain network connectivity associated with centralized pain, by analyzing the 
brain measures using computational algorithms 
Optimize therapeutic benefit by determining a modification to therapeutic intervention, 
such as a cortical stimulation signal, that corresponds to the measures and statistics 
associated with the brain measures, such as measures and statistics of EEG data, in ways 
such as making a comparison between such measures and statistics and one or more 
parameters of a cortical stimulation signal 
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Form a cap comprising one or more stimulating electrodes and one or more ground 
electrodes and further comprising means to fit the cap to the shape of a subject's head 
such as flexible bands configured to carry the electrodes and including arms and tabs 
that connect when placed on a subject's head 
Position the cap so that it is worn on a subject's head in a predetermined 
orientation that creates a vector path extending between a stimulating electrode 
and a ground electrode and that passes through or proximate a desired area of 
brain tissues to be stimulated 
Deliver one or more cortical stimulation signals to a subject via the cap 
Fig. 20 
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Provide a cap comprising flexible bands that connect to fit the shape of a head and also 
comprising electrodes for measuring EEG signals and delivering cortical stimulation 
signals, and provide on the cap a cap identifier and an allowed use indicator that 
represents a predetermined number of allowed uses for the cap and that comprises an 
information storage device such as a bar code or an RFID chip 
Gain access to stored information in the cap identifier and the cap allowed use 
indicator, such as by using a reader such as a bar Code reader or an RFID chip reader 
Compare the stored information against a database of information gathered from caps 
that have previously been used, such as an information database stored locally on an 
apparatus for diagnosing and treating centralized pain or an information database 
stored in a central location and accessed via a network connection 
Compare the number of allowed uses indicated in the cap allowed use indicator against 
the previous cap use number stored in the cap information database 
Configure an apparatus for diagnosing and treating centralized pain to allow use of the 
cap only if the cap information database indicates that the previous cap use number is 
less than the number of allowed uses indicated by the cap allowed use indicator 
Prevent a cap from being used more than a predetermined number of times by adding 
information about a cap's use to the cap information database upon use of the cap 
End 
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Diagnose one or more brain conditions associated with centralized pain, such as that 
arising from central sensitivity or from abnormal network connectivity, by assessing the 
brain of a subject suffering from pain, either by direct assessment techniques such as 
neuroimaging, or by indirect assessment such as analysis of other biological measures 
Locate at least one area of abnormal brain measure associated with an abnormal brain 
Condition producing the centralized pain 
Alter the one or more brain conditions in such a way as to alleviate the centralized pain 
in combination with treatment of at least one other coexisting physical condition by 
applying a cortical stimulation signal, such as an AMPWM signal or other waveform 
configured to minimize tissue impedance, to tissues Corresponding to at least one area 
of abnormal brain measure 
Fig. 22 
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Diagnose one or more brain conditions associated with centralized pain such as that 
arising from central sensitivity or from abnormal network connectivity, by assessing the 
brain of a subject suffering from pain, either by direct assessment techniques such as 
neuroimaging, or by indirect assessment such as analysis of other biological measures 
Locate at least one area of abnormal brain measure associated with an abnormal brain 
condition producing the centralized pain 
Alter the one or more brain conditions in such a way as to alleviate the centralized pain 
by applying a cortical stimulation signal, such as an AMPWM signal or other waveform 
configured to minimize tissue impedance, to tissues corresponding to at least one area 
of abnormal brain measure, in combination with at least one other form of treatment, 
such as administering to the subject one or more pharmaceutical agents utilized to 
affect symptoms of centralized pain 
Fig. 23 
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Select a subject suffering from abnormal brain network connectivity Such as increased or reduced 
functional network connectivity, or increased or reduced effective network connectivity 
identify at least one target network of the subject's brain by administering one or more 
tests, such as a neuroimaging test or a brain response test, to detect the presence and 
location of one or more abnormal network connections 
Administer one or more tests, such as a neuroimaging test or a brain response test, to 
identify at least one target region of tissues that include at least one part of a network 
to be altered or has network Connections functionally interrelated with the at least one 
target network 
Alter the network connectivity in the at least one target network by stimulating the at least 
one target region of tissues either in an invasive manner, or in a non-invasive manner using 
electrical stimulation and/or magnetic stimulation including the administration of an 
AMPWM signal applied to the target region from outside the subject and transmitted 
through intervening tissues, such that the network connectivity is altered 
End 
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Select a subject suffering from abnormal brain network connectivity such as increased or reduced 
functional network connectivity, or increased or reduced effective network connectivity 
identify at least one target network of the subject's brain by administering one or more 
tests, such as a neuroimaging test or a brain response test, to detect the presence and 
iocation of one or more abnormal network connections 
Administer one or more tests, such as a neuroimaging test or a brain response test, to 
identify at least one target region of tissues that include at least one part of a network 
to be altered or has network connections functionally interrelated with the at least one 
target network 
Administer one or more pharmaceutical agents formulated to alter brain network 
connectivity; timed such that the one or more pharmaceutical agents are present in the 
subject during at least a portion of a time during which the stimulating step is executed 
Alter the network connectivity in the at least one target network by stimulating the at least 
one target region of tissues either in an invasive manner, or in a non-invasive manner using 
electrical stimulation and/or magnetic stimulation including the administration of an 
AMPWM signal applied to the target region from outside the subject and transmitted 
through intervening tissues, such that the network connectivity is altered 
End 
Fig. 25 
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METHOD AND APPARATUS FOR TREATING 
CENTRALIZED PAN 
CROSS-REFERENCES TO RELATED 
APPLICATIONS 
0001. This application is a 371 (US national phase) of 
PCT/US2013/040045, filed May 8, 2013, which claims pri 
ority to U.S. Ser. No. 61/644,049, filed May 8, 2012; and a 
continuation-in-part of U.S. Ser. No. 13/942,246, filed Jul. 
15, 2013; and claims the benefit of PCT/US2009/032639, 
filed Jan. 30, 2009. 
TECHNICAL FIELD 
0002 The present invention relates generally to the treat 
ment of pain. More specifically, the present invention relates 
to methods and apparatuses for treating pain involving abnor 
mal pain processing functions and mechanisms in the brain. 
BACKGROUND 
0003) Nociceptive pain is known to arise from stimulation 
of peripheral nerve endings. The peripheral nociceptive sig 
nal is transmitted through the spinal cord to the brain, where 
it is processed through numerous pain-processing networks. 
Descending pathways from the brain to the spinal cord Sub 
sequently modulate pain signals, thereby increasing or 
decreasing pain perception. 
0004. However, it is also known that enhanced activation 
of central pain-processing pathways and networks, through 
mechanisms such as neuroplastic changes in central neuronal 
activity and network connectivity, can lead to spontaneous 
pain in the absence of peripheral nociceptive input. When this 
occurs, pain is said to have “centralized, which results in 
lower pain thresholds, secondary hyperalgesia in uninjured 
areas, and Sustained pain potentiation. Brain-related central 
ized pain is thought to play a prominent role in chronic pain 
conditions. 
0005 Centralized pain is generally thought of as an out 
come of central sensitivity (CS), which is also known as 
central sensitization, central augmentation, and central 
hypersensitivity among other terms. CS mechanisms in the 
brain have been implicated in the pathology of allodynia, 
which is the term used to describe a condition where pain is 
caused by a stimulus that does not normally provoke pain. CS 
mechanisms in the brain have also been implicated in hype 
ralgesia, which is the term used to describe a condition in 
which pain perceived from a stimulus is greater than what 
would normally be expected from that stimulus. Put simply, 
in central sensitivity the brain magnifies painful stimuli and 
eventually magnifies even associated non-painful stimuli. As 
pointed out in Latremoliere and Woolfe (1), because CS 
results from changes in the properties of neurons in the central 
nervous system, the pain is no longer coupled, as acute noci 
ceptive pain is, to the presence, intensity, or duration of nox 
ious peripheral stimuli arising from both neuropathic and 
inflammatory sources. Further, in chronic pain conditions the 
increased excitability caused by CS far outlasts the initiating 
noxious stimulus, that is, the nociceptive input that causes the 
pain to occur in the first place. 
0006 Before CS was discovered, typically only two mod 
els of pain were contemplated. The first is the aforementioned 
nociceptive pain model, by which specific pain pathways are 
activated by peripheral pain stimuli, and the amplitude and 
duration of the pain experienced is determined entirely by the 
May 21, 2015 
intensity and timing of the peripheral pain inputs. The second 
model contemplates gate controls in the central nervous sys 
tem that open and close, thus enabling or preventing pain. 
Medical science now recognizes CS as a third and unique 
model that contemplates neuroplastic changes in the func 
tional properties and network connectivity of the central ner 
Vous system. For example, the level of resting brain activity 
within multiple networks (e.g. functional network connectiv 
ity and effective network connectivity) is now known to be 
associated with spontaneous pain in patients having central 
ized pain (2, 3). CS leads to reductions in pain threshold, 
increases in the magnitude and duration of responses to nox 
ious input, and permits normally innocuous inputs to generate 
pain sensations. In addition, CS is also believed to be relevant 
in Somatic symptoms associated with painful conditions, 
including but not limited to fatigue and sleep disorders. 
0007. The brain's role in CS is being increasingly revealed 
and understood in neuroscience, due in large part to the 
advent of functional brain imaging technologies. For 
example, Lee et al. (4) used functional magnetic resonance 
imaging (fMRI) to examine the extent to which brain activity 
contributes to the maintenance of CS in humans. When the 
intensity of pain during CS was matched to the intensity of 
pain during normal states, activity within the brainstem, 
including the mesencephalic pontine reticular formation and 
the anterior thalami, remained at an increased level during 
CS. Regarding brain areas related to the consequence of 
increased pain perception during CS, cortical activity, mainly 
in the primary somatosensory area, has been significantly 
correlated with the intensity of pain attributable to both the 
force of noxious stimulation used, and the state in which 
noxious stimulation was applied. 
0008 Borsook et al. (5) reviewed the literature on brain 
activity using neuroimaging technologies. Their review 
details evidence of alterations in multiple sub-cortical and 
cortical processing mechanisms. Those alterations include 
sensory, emotional/affective, cognitive, and modulatory sys 
tems that are present in chronic pain. The authors note these 
findings provide evidence that increases understanding of the 
importance of the role of numerous brain regions in the cen 
tralization of pain and the contributions of those regions to the 
altered brain states associated with chronic pain conditions. 
Similarly, Schweinhardt and Bushnell (6) review neuroimag 
ing evidence of the active and enhanced modulatory role that 
the brain plays in pain processing in chronic pain patients. 
Schwienhardt and Bushnell also cite findings that brain acti 
Vations in chronic pain involve brain circuitry not normally 
activated by acute nociceptive pain. 
0009. Because of this emerging understanding, the role of 
CS is increasingly being shown to be pathological in seem 
ingly unrelated chronic pain conditions and syndromes 
including fibromyalgia, complex regional pain syndrome, 
phantom pain, and migraine headaches. Yunus (7) identifies 
no less than 14 common syndromes that lack structural 
pathology yet have CS as a common mechanism. These con 
ditions further include chronic fatigue syndrome, irritable 
bowel syndrome, tension-type headaches, temporomandibu 
lar disorder, myofascial pain syndrome, regional soft-tissue 
pain syndrome, restless leg syndrome, periodic limb move 
ments in sleep, multiple chemical sensitivity, primary dys 
menorrhea, female urethral syndrome, interstitial cystitis, 
and post-traumatic stress disorder. Yunus also notes that CS 
may play a significant role in the pain associated with depres 
sion and in Gulf War Syndrome. 
US 2015/O 141529 A1 
0010 Giesecke et al. (8) used fMRI to demonstrate aug 
mented central pain processing in patients with idiopathic 
chronic low back pain and fibromyalgia. Indeed, when equal 
levels of mechanical pressure intended to elicit a painful 
response were applied to patients and to normal controls, 
patients with chronic low back pain and fibromyalgia expe 
rienced significantly more pain and showed more extensive, 
common patterns of neuronal activation in pain-related cor 
tical areas of the brain than did the controls. Thus, CS may 
play an important role in persons with chronic low back pain 
that persists without identifiable physical pathology. 
0011. The role of CS in persistent inflammatory condi 
tions is also gaining recognition. In Gwilym et al. (9), fMRI 
illustrated significantly greater brainactivation in osteoarthri 
tis (OA) patients in response to stimulation of their referred 
pain areas (i.e. areas where pain persists but do not exhibitOA 
or related inflammation) compared with healthy controls, and 
the magnitude of this activation positively correlated with the 
extent of neuropathic-like elements to the patient’s pain. The 
role of CS in osteoarthritis has been the subject of several 
other investigations (10, 11, 12). As detailed in Imamura et al. 
(13), the refractory, disabling pain associated with knee OA is 
usually treated with total knee replacement. However, a com 
parison of OA patients with healthy normal controls showed 
patients with knee OA had significantly lower pressure pain 
thresholds (PPT) over widespread evaluated structures 
beyond the knee. The lower PPT values were correlated with 
higher pain intensity, higher disability Scores, and with poorer 
quality of life. This suggests that pain in these patients might 
be more associated with CS than with peripheral inflamma 
tion and injury. As the authors point out, the implications of 
the role of CS, and its potential for modulation, may provide 
exciting and innovative cost effective therapeutic tools to 
control pain, reduce disability, and improve quality of life in 
knee OA patients. 
0012 Yet, the treatment of CS is a challenging task. As 
stated by Latremoliere and Woolfe (1), “The complexity is 
daunting because the essence of central sensitization is a 
constantly changing mosaic of alterations in membrane excit 
ability, reductions in inhibitory transmission, and increases in 
synaptic efficacy, mediated by many converging and diverg 
ing molecular players on a background of phenotypic 
Switches and structural alterations. Some centrally-acting 
pharmaceutical agents such as gabapentin (14.15), ketamine 
(16), propofol (17) and anti-tumor necrosis factor alpha 
(TNF-alpha) therapy (18), just to name a few, have evidence 
of efficacy in treating CS. The patent literature has examples 
in the art of pharmaceutical use as a therapeutic agent for 
treating CS. For example, the use of dimiracetam for treat 
ment of hyperalgesia and allodynia caused by central sensi 
tization in chronic pain has been taught. Further, compounds 
associated with (R)-2-acetamido-N-benzyl-3-methoxypropi 
onamide have been taught for use in treating central neuro 
pathic pain, including "neurological disorders characterized 
by persistence of pain and hypersensitivity in a body region.” 
0013 Another relevant consideration is that analyses of 
numerous brain imaging and functional measures, including 
electroencephalographic (EEG) measures (19), have been 
shown to produce measures related to brain networks and 
functional connectivity that correlate to findings produced by 
fMRI imaging (20). Thus, the presence of brain activity asso 
ciated with CS, and hence centralized pain, can be determined 
using EEG measures and analysis. 
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SUMMARY 
0035. A method is provided for alleviating centralized 
pain. The method may include the steps of assessing the brain 
ofa Subject suffering from pain, diagnosing one or more brain 
conditions associated with centralized pain, and locating at 
least one area of abnormal brain measure associated with an 
abnormal brain condition producing the centralized pain. 
Also, a cortical stimulation signal may be applied to at least 
one area of abnormal brain measure to alter the one or more 
brain conditions in Such a way as to alleviate the centralized 
pain. 
0036. A method is provided for assessing a brain to deter 
mine the presence of centralized pain, which may include the 
use of a brain response test comprising one or more neuroim 
aging tests performed before, during and after the application 
of any one or more sensory stimulations to cause one or more 
brain responses. 
0037. A method is provided for predicting symptom sever 
ity in individuals having centralized pain, which may include 
the steps of executing brain response testing on a Subject, 
obtaining brain measures associated with centralized pain in 
the Subject by analyzing findings from the brain response 
testing, and correlating the brain measures to measures of 
symptom severity. 
0038 A method is provided for determining the effect of 
therapeutic intervention in alleviating symptoms of central 
ized pain, which may include the steps of executing brain 
response testing on a Subject, obtaining brain measures asso 
ciated with centralized pain in the Subject by analyzing find 
ings from the brain response testing, and correlating the brain 
measures to measures of the effect of therapeutic interven 
tion. 
0039. A method is provided for determining points for 
application of cortical stimulation for alleviating centralized 
pain by analyzing a brain response test. 
0040. A method is provided for optimizing an intervention 
for alleviating centralized pain, which may include the steps 
of collecting brain measures associated with one or more 
abnormal brain conditions associated with centralized pain 
during a time period at or near the time of a therapeutic 
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intervention, analyzing the brain measures by computational 
algorithms to determine measures and Statistics associated 
with the brain measures, and using the measures and statistics 
to modify parameters of an intervention for the purposes of 
optimizing therapeutic benefit. 
0041 An apparatus for diagnosing and treating central 
ized pain is provided, which may comprise a cap configured 
to be worn on a subject’s head and a series of interconnectable 
flexible bands configured to include arms and tabs that con 
nect when placed on ahead to form a means to fit the shape of 
the head. 
0042 An apparatus for diagnosing and treating central 
ized pain is provided, which may comprise a cap configured 
to be worn on a subject’s head and interconnected flexible 
bands that form the cap and are configured to position one or 
more electrodes to measure one or more EEG signals from a 
Subject and/or deliver one or more cortical stimulation signals 
to a subject. 
0043. A method is provided for delivering one or more 
cortical stimulation signals to a Subject that may include the 
use of an apparatus comprising one or more electrodes 
including one or more ground electrodes positioned in flex 
ible bands configured to include arms and tabs that connect 
when placed on a head to form a cap to fit the shape of the 
head. 
0044 An abnormal brain function diagnostic and treat 
ment apparatus is provided, which may comprise a cap con 
figured to be worn on a subjects head and may also comprise 
one or more electrodes positioned to contact a subjects head 
when the Subject is wearing the cap, and the cap may also 
comprise a memory configured to store information. 
0045. A method is provided for preventing a cap from 
being used more than a predetermined number of times. The 
method may include providing a cap identifier on the cap and 
an allowed use indicator representing a predetermined num 
ber of allowed uses for the cap. The method also may include 
gaining access to stored information in the cap identifier and 
the cap allowed use indicator, comparing the stored informa 
tion against a database of information on caps that have pre 
viously been used, and comparing the number of allowed uses 
indicated in the cap allowed use indicator against the previous 
cap use number stored in the cap information database. The 
method also may include configuring an apparatus for diag 
nosing and treating centralized pain to allow use of the cap 
only if the cap information database indicates that the previ 
ous cap use number is less than the number of allowed uses 
indicated by the cap allowed use indicator. 
0046. A method is provided for altering brain network 
connectivity in a Subject. The method may include the steps of 
identifying a target network in the Subject's brain, identifying 
a target region of tissues, and stimulating the target region of 
tissues to alter the brain network connectivity. 
0047. Additional advantages and novel features of the 
invention will be set forth in part in the description that 
follows, and in part will become more apparent to those 
skilled in the art upon examination of the following or upon 
learning by practice of the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0048. These and other features and advantages will 
become apparent to those skilled in the artin connection with 
the following detailed description, drawings, photographs, 
and appendices, in which: 
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0049 FIG. 1 is a flow chart depicting a treatment method; 
0050 FIG. 2 is a schematic diagram showing an apparatus 
for treating a brain-related chronic pain disorder, 
0051 FIG. 3 is a schematic diagram showing a signal 
generating circuit of the apparatus of FIG. 2; 
0052 FIG. 4 is a schematic diagram showing an embodi 
ment of an apparatus for treating a brain-related chronic pain 
disorder and showing a therapy cap of the apparatus and a 
Subjects head cut-away to reveal electrical stimulation signal 
paths relative to target areas of the Subject's brain tissue; 
0053 FIG. 5 is a schematic diagram showing an embodi 
ment of an apparatus for treating a brain-related chronic pain 
disorder and showing atherapy cap of the apparatus cut-away 
to reveal an RFID chip carried by the cap; 
0054 FIG. 6 is a schematic diagram showing an embodi 
ment of an apparatus for treating a brain-related chronic pain 
disorder and showing atherapy cap of the apparatus cut-away 
to reveal a programmable memory circuit carried by the cap; 
0055 FIG. 7 is a schematic diagram showing an embodi 
ment of an apparatus for diagnosing and treating centralized 
pain; 
0056 FIG. 8 is a schematic diagram showing a signal 
generator circuit embodiment of the apparatus of FIG. 7: 
0057 FIG. 9 is a schematic diagram showing an embodi 
ment of a cap apparatus configured to be worn on a subjects 
head; 
0058 FIG. 10 is another schematic diagram showing an 
embodiment of a cap apparatus configured to be worn on a 
subjects head; 
0059 FIG. 11 is a flow diagram of a method of alleviating 
centralized pain by diagnosing brain conditions associated 
with centralized pain and applying a cortical stimulation sig 
nal; 
0060 FIG. 12 is a flow diagram of a method of diagnosing 
centralized pain based on analyzing findings from one or 
more brain response tests; 
0061 FIG. 13 is a flow diagram of a method of determin 
ing the presence of centralized pain by determining brain 
response test abnormalities consistent with centralized pain; 
0062 FIG. 14 is a flow diagram of a method of predicting 
symptom severity by correlating measures of a brain response 
test to measures of symptom severity; 
0063 FIG. 15 is a flow diagram of a method of determin 
ing the effect of therapeutic intervention by correlating mea 
sures of a brain response test to measures of the effect of 
therapeutic intervention; 
0064 FIG. 16 is a flow diagram of a method of determin 
ing points for application of cortical stimulation using analy 
sis of findings from a brain response test; 
0065 FIG. 17 is a flow diagram of a method of assessing 
the effectiveness of a therapeutic intervention; 
0066 FIG. 18 is a flow diagram of a method of transferring 
cortical stimulation signal parameters via electronic means; 
0067 FIG. 19 is a flow diagram of a method of optimizing 
therapeutic benefit of a cortical stimulation signal; 
0068 FIG. 20 is a flow diagram of a method of forming 
and positioning a cap to deliver cortical stimulation signals; 
0069 FIG. 21 is a flow diagram of a method of preventing 
a cap from being used more than a predetermined number of 
times; 
0070 FIG.22 is a flow diagram of a method of alleviating 
centralized pain by applying a cortical stimulation signal in 
combination with treatment of another coexisting physical 
condition; 
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0071 FIG. 23 is a flow diagram of a method of a method of 
alleviating centralized pain by applying a cortical stimulation 
signal in combination with administering a pharmaceutical 
agent, 
0072 FIG. 24 is a flow diagram of a method for altering 
network connectivity in a brain by applying a cortical stimu 
lation signal; and 
0073 FIG. 25 is a flow diagram of a method for altering 
network connectivity in a brain by administering a pharma 
ceutical agent and applying a cortical stimulation signal. 
DETAILED DESCRIPTION 
0074. In the following description of the disclosed appa 
ratus and methods, the term “centralized pain' is intended to 
mean any form of pain, whether chronic or acute, that is 
enhanced in its characteristics; Such as magnitude, duration 
and scope; due to abnormalbrainactivity associated with pain 
processing. Such brain activity may include, but is not limited 
to, central sensitivity and network connectivity. 
(0075. The term “central sensitivity” is intended to mean 
any central nervous system condition pathologically related 
to hyperalgesia, allodynia, reductions in pain threshold, 
increases in the magnitude and duration of responses to nox 
ious input, results in normally innocuous inputs to generate 
pain sensations, or results in non-painful symptoms associ 
ated with increases in central nervous system responsiveness. 
Central sensitivity is also known by alternate terms that 
include but are not limited to “central sensitization”, “central 
pain', 'central augmentation.” and “central hypersensitiv 
ity”. 
0076 Central sensitivity is not a manifestation or cause of 
an individual symptom or condition. Instead, central sensi 
tivity results in a worsening of the effect or magnitude of one 
or more symptoms because of a central nervous system con 
dition that is independent of the cause of the one or more 
symptoms per se. Thus, any method of treatment of central 
sensitivity is fundamentally different from treatment of a 
specific symptom. For example, treatment of pain augmenta 
tion by central sensitivity is inherently different than treat 
ment of pain under traditional nociceptive models of pain. 
0077. The terms “network connections” and “network 
connectivity” are intended to mean various forms of relation 
ships between brain regions involved in processing of infor 
mation Such as pain. For example, “functional connectivity” 
refers to a statistical correlation between the activities of 
different brain regions. “Effective connectivity” denotes not 
simply a statistical but a causal influence between two brain 
regions. 
(0078. The term “alleviate' or “alleviating is intended to 
mean the act of reducing, making less severe, mitigating, 
treating, or eliminating a condition and/or its symptoms for 
any period of time. 
0079 Except where the context requires otherwise, the 
term “comprise' and variations of the term, such as “com 
prising”, “comprises” and “comprised are not intended to be 
exclusive. Where, for example, a form of the word “com 
prise' is used to refer to one or more additives, components, 
integers or steps; its use is not intended to exclude other 
additives, components, integers or steps. 
0080 Where the terms “integral” or “integrated” are used 
to describe a relationship between two or more elements, the 
terms are intended to indicate that such elements are joined 
together in a manner that does not allow separation of ele 
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ments from one another without diminishing or destroying a 
function of one or more of the elements. 
0081. The term “stimulating is intended to mean the 
transmitting of any energy signal generated by a stimulation 
device Such as an electrical stimulator, or by a magnetic 
stimulator Such as a transcranial magnetic stimulator, to the 
brain of a Subject for the purpose of influencing any function 
or physiological state of the Subject’s brain that is at least one 
part of a pathway of centralized pain. 
0082. The term “stimulation signal' is intended to mean 
any energy signal used in the process of stimulating a tissue 
Such as a brain. Other terms used to refer to Such a signal may 
include but are not limited to “cortical stimulation”, “neuro 
modulation' and “neurostimulation'. 
0083. The term “neuroimaging test” is intended to mean 
any medical test that provides visual indication, measures, or 
other data that can be used to make an assessment about 
central nervous system function, including brain function. 
Types of tests that the term “neuroimaging test may be used 
to refer to include, but are not limited to, magnetic resonance 
imaging, computer aided tomography, positron emission 
tomography, or single photon emission computed tomogra 
phy, and may also include brain electrical function tests Such 
as electroencephalography or magnetoencephalography. 
0084. The term “brain activities” is intended to refer to any 
brain activities that are known in the art to be associated with 
central sensitivity. Such brain activities are intended to 
include, but are not limited to abnormal function, abnormal 
response, abnormal regions of activation, abnormal network 
connectivity, abnormal release of neurochemicals, abnormal 
uptake of neurochemicals, abnormal electrical activity, or 
abnormal metabolism. 
0085. The term “brain function' is intended to mean any 
action or process of a brain in the brain's normal course of 
operation. 
I0086. The term “spectral segments” is intended to mean 
frequency components of an electrical signal that includes 
individual frequency components, and in the case of an EEG 
signal, that includes groupings of frequency components 
commonly known as “frequency bands'. Such bands includ 
ing, but not limited to the “delta” band (nominally 1-3.5 
hertz), the “theta' band (nominally 4-7.5 hertz), the “alpha 
band (nominally 8-12 hertz) and the “beta’ band (nominally 
12.5-25 hertz). 
I0087. The term “resting EEG” is intended to mean elec 
troencephalogram signals that are collected with the Subjects 
eyes either open or closed and during periods of no significant 
physical activity, mental activity, or any otherform of engage 
ment that may cause the brain to be stimulated significantly or 
engaged in elevated brain function. 
0088. The term “biopotential” is intended to mean any 
electrical signal representing a measurable physiological 
function or state. Such electrical signals may include, but are 
not limited to, electroencephalogram signals, magnetoen 
cephalogram signals, electromyogram signals, signals repre 
senting measures of vital signs and signals representing mea 
Sures of organ function. 
I0089. With reference to FIGS. 1a-1e, a method is provided 
for treating a brain-related chronic pain disorder. The method 
includes assessing the brain function of a Subject Suffering 
from chronic pain, diagnosing a chronic pain-related abnor 
mal brain condition, locating at least one area of abnormal 
brain activity associated with the abnormal brain condition 
and mitigating the abnormal brain activity by applying a 
May 21, 2015 
neuromodulation signal to tissues corresponding to the at 
least one area of abnormal brain activity. Alternatively, the 
neuromodulation signal comprises waveforms designed to 
minimize tissue impedance while effecting noninvasive neu 
romodulation. Treatment effect is realized when abnormal 
brain function has been improved or corrected. 
0090. A physical assessment may first be performed of a 
human Subject presenting with a complaint of symptoms 
characteristic of a chronic pain condition Such as fibromyal 
gia. The physical assessment may include, among other 
things, a determination of chronic widespread pain, sleep 
difficulty, fatigue, morning stiffness of the muscles and joints, 
cognitive difficulty, and other symptoms associated with the 
condition. The physical assessment may also include tests 
performed to exclude various non-fibromyalgia conditions as 
the cause of the symptoms. Such further testing may include 
palpation of tissues to elicit a painful response, Such as pal 
pation offibromyalgia tender points in the manner prescribed 
by the American College of Rheumatology, with Such palpa 
tion being performed to determine whether the subject has an 
abnormal sensitivity to pain. 
0091. In the absence of an alternate, non-fibromyalgia 
diagnosis, an electroencephalogram (EEG) test may be per 
formed in addition to the physical assessment, whereby the 
EEG test is performed utilizing methods and apparatus well 
known in the art. Specifically, the Subject may be made com 
fortable by, for example, being seated, or reclined. Prepara 
tion of the Scalp in accordance with commonly followed 
procedures for performing a clinical EEG may be done by a 
person of sufficient competence. EEG electrodes may then be 
adapted to be worn on the scalp, preferably in Scalp locations 
identified as the “International 10-20 standard sites, using 
common methods of affixing the electrodes Such that they rest 
on or otherwise contact tissues. 
0092. While any number of electrodes may be used, a 
preferred number is either 19 or 24, in accordance with the 
number of electrode sites used to construct various indepen 
dent databases utilized to represent the EEG of a healthy 
normal population, and to facilitate quantitative assessment 
(qEEG) of the subjects EEG. Methods involving qBEG 
include a number of mathematical analyses utilized to make 
statistical comparisons between the Subject’s qEEG and a 
database of qEEGs of either healthy normal individuals’ brain 
functions or the brain functions of individuals suffering from 
chronic pain related brain function conditions. 
(0093. Records of the subject's EEG from each electrode 
site may then be acquired under the conditions of both their 
eyes being closed and their eyes being open, with each con 
dition producing a separate data record. In other words, an 
“eyes open' EEG record may be obtained, which includes 
EEG data obtained from each electrode site while the sub 
ject’s eyes are open and an “eyes closed EEG record may be 
obtained, which includes EEG data obtained from each elec 
trode site while the subject’s eyes are closed. Preferably, a 
minimum of five minutes of EEG data may be obtained from 
each electrode site for each "eyes open EEG record and a 
minimum of five minutes of EEG data may be obtained from 
each electrode site for each "eyes closed EEG record to 
assure that enough EEG data is recorded to produce statisti 
cally significant samples from each electrode site, both with 
the subject’s eyes open and with the subject’s eyes closed. 
This is further described below. 
0094 Preferably, an additional test may be performed in 
which at least one additional EEG record is made that 
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includes EEG data obtained at each electrode site while the 
subject’s eyes are closed. In this test, henceforth referred to as 
a “tender point palpation (TPP) test”, a number of tender 
points on the Subject’s body, preferably ranging between one 
and 18, are identified and serially palpated with an algometer. 
Preferably, four tender points may be chosen, and, preferably, 
those four points include tender points adjacent the right and 
left lateral epicondyle of the arms approximately two centi 
meters distal of the elbows, and tender points adjacent the 
right and left costochondral junctions of the second rib. 
0095. The TPP test may be executed by acquiring an EEG 
record (“TPP” EEG record) including EEG data obtained 
from the electrode sites for a first tender point by first com 
mencing the acquisition of EEG data and then, a short period 
of time later, commencing palpation of the first tender point. 
Preferably, the period of time between the commencement of 
data acquisition and the commencement of palpation of the 
first tender point may be between one and 300 seconds. Pal 
pation of the first tenderpoint may be accomplished by press 
ing on the tender point preferably pressing or palpating 
through the use of an algometer, and preferably at a rate of 
approximately one kilogram per centimeter squared per sec 
ond, until the Subject reports a painful sensation or until 
reaching a pressure of 4 kilograms per centimeter squared— 
whichever occurs first. Preferably, palpation pressure may be 
removed as soon as the Subject reports a painful sensation. A 
record is made of the amount of the pressure being applied at 
the moment the Subject reports a painful sensation. 
0096. Further according to the TPP test method, the 
recording of the “eyes closed EEG may continue for a period 
of time after release of palpation pressure, preferably between 
1 and 300 seconds, and most preferably, for at least 60 sec 
onds. Following this period, a second and Subsequent tender 
point may be serially palpated with an algometer in the same 
manner as described for the first, with “TPP” EEG records 
being recorded for each by recording the “eyes closed EEG 
for each site in the manner described with regard to obtaining 
the “TPP” EEG record for the first site. This process may be 
repeated for each chosen tender point. Accordingly, the 
resulting EEG data record includes the “TPP” EEG records 
acquired for each chosen tender point. 
0097. The “TPP” EEG records may be acquired for a 
period of time that is sufficient to extract from each “TPP 
EEG record a minimum of 60 seconds of “clean EEG data, 
that is, data free of extraneous electrical noise Such as that 
from electromyographic movement. Preferably, all EEG 
records (“eyes open EEG records, “eyes closed EEG 
records, and “TPP” EEG records) may be individually edited 
to provide from each EEG recorda minimum of 60 seconds of 
clean EEG. Preferably, the clean data is obtained to present a 
high degree of statistical consistency. Such measures as 
“Split-Half reliability, which is the ratio of variance between 
the even and odd seconds of the time series of selected clean 
EEG; and “Test Re-test” reliability, which is the ratio of 
variance between the first half and the second half of the 
selected clean EEG segments may be used. Preferably, clean 
EEG data is obtained such that measures of these ratios are a 
minimum of 0.95 and 0.90 respectively, which is consistent 
with levels of reliability commonly published in EEG litera 
ture. 
0098. With regard to the TPP test method, clean data 
includes only that EEG data acquired after palpation of a 
tender point, and does not include any EEG data acquired 
during the palpation of a tender point. In addition, to assess 
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the stability of a “TPP” EEG record, EEG data acquired 
before palpation of a tenderpoint may be removed, edited and 
statistically compared to like data in the “eyes closed EEG 
record obtained from the “eyes closed EEG test. Stability of 
the “eyes closed” and “TPP” EEG records is indicated by a 
finding that there is no statistically significant difference 
between the “eyes closed EEG record and the pre-palpation 
portion of the “TPP EEG record. A contrary finding indi 
cates instability and a need to repeat the EEG tests. 
(0099 Further to the method, and in the preferred embodi 
ment, clean “eyes open”, “eyes closed”, and “PPT EEG 
records may be then mathematically analyzed for various 
time domain and frequency domain parameters of their 
respective electrical signals. These analyses may include, but 
are not limited to Voltage analysis, current analysis, Voltage 
and current analysis, frequency spectrum analysis using Fast 
Fourier transform analysis, frequency spectrum analysis 
using a wavelet analysis method, frequency spectrum analy 
sis using absolute power analysis method, frequency spec 
trum analysis using relative power analysis method, fre 
quency spectrum analysis using phase analysis method, 
frequency spectrum analysis using coherence analysis 
method, frequency spectrum analysis using amplitude sym 
metry analysis method, and localization of electrical activity 
in the brain using inverse EEG computation analysis. 
0100 Findings from the aforementioned analyses may 
then be statistically compared to the same parameters deter 
mined from “eyes open”, “eyes closed”, and “PPT EEG 
records taken from an age and gender matched database of 
healthy normal individuals. Such statistical analyses may 
include, but are not limited to deviations from a standard 
normal distribution. Findings of Statistically significant 
abnormal deviation, or lack thereof, may then be presented in 
a graphical or numerical format for analysis by a competent 
health care professional or person of similar expertise. 
0101 EEG abnormalities consistent with those observed 
in a sample population of fibromyalgia patients may include, 
but are not limited to one or more of the following: (1) an 
overall reduction in EEG power across all spectra in either of 
the “eyes open' or “eyes closed’ conditions; (2) statistically 
significant low EEG power levels in frontal or temporal 
regions of any of the delta (1-3.5 hertz), theta (4-7.5 hertz) or 
alpha (8-12 hertz) frequency segments of EEG for the “eyes 
closed’ condition; (3) statistically significant low coherence 
among the frontal EEG sites for the delta or theta EEG seg 
ments in either of the “eyes closed’ or “eyes open' condi 
tions; (4) statistically significant high relative beta (12.5-25 
hertz) absolute power in the parietal region of the brain for 
either of the “eyes closed’ or “eyes open conditions. The 
magnitude of statistical variation considered statistically 
“significant may vary depending on the application. For 
example, in research, a difference between a sample and a 
population measure generally has to have a p-value of 0.01 or 
less for the difference to be considered statistically “signifi 
cant'. However, inclinical application statistically significant 
differences may be declared with p-values at the 0.1 level or 
less. 
0102. Further EEG abnormalities consistent with those 
observed in a sample population offibromyalgia patients, and 
drawn particularly to the TPP test method, may include but 
are not limited to a finding of (1) a statistically significant 
increase in EEG absolute power, particularly in the alpha and 
beta segments, in the parietal, occipital, and temporal areas of 
the brain as compared to the “eyes closed EEG record ("eyes 
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closed EEG findings without tender point palpation) for the 
same Subject; or (2) a statistically significant increase in 
coherence in the alpha or beta segment of EEG. The following 
are the results of tests of the predictive value of TPP sensitiv 
ity analysis, obtained when TPP testing was utilized on 19 
fibromyalgia patients and compared to TPP testing done on 
nine healthy normal controls: 
Positive 
Test Criterion for Making a Diagnosis Sensi- Speci- Predictive 
of Fibromyalgia tivity ficity Value 
An increase in alpha EEG of at least 20% 63% 89% 92% 
in at least one occipital or parietal site 
An increase in alpha EEG of at least 84% 78% 89% 
20% in at least one temporal site 
The total regions of increase in alpha EEG 74%. 100% 100% 
of at least 20% are greater than two 
Alpha EEG coherence increases by at 84% 88% 94% 
least 20% in at least 30 out of 171 
possible site combinations 
At least two (2) positive findings occur in 90%. 100% 100% 
any of the four previous tests 
*Based on comparison of TPPEEG data against eyes closed EEG data 
0103) A diagnosis of fibromyalgia may be made when 
physical assessment findings that Support a diagnosis of 
fibromyalgia are augmented by making a quantitative assess 
ment including but not necessarily limited to a statistical 
comparison between the subject’s qBEG and a database of 
quantitative assessments of either healthy normal individuals 
or individuals suffering from a chronic pain related abnormal 
brain function condition Such as fibromyalgia. In the pre 
ferred embodiment, statistical findings that Support a diagno 
sis of fibromyalgia may include, but are not necessarily lim 
ited to, (1) an abnormal finding resulting from the TPP test, 
preferably a finding of a statistically significant increase in 
EEG absolute power, and particularly in the alpha and beta 
segments, in the parietal, occipital, and temporal areas of the 
brain as compared to the “eyes closed findings without ten 
derpoint palpation for the same subject; and preferably (2) an 
abnormal finding resulting from the “eyes closed EEG test, 
preferably statistically significant low EEG power levels in 
frontal or temporal regions of any of the delta, theta or alpha 
frequency segments of EEG for the “eyes closed’ condition, 
and most preferably with an additional finding of statistically 
significant low coherence among the frontal EEG sites for the 
delta or theta EEG segments. Alternately, fibromyalgia may 
be diagnosed by statistically comparing a subjects one or 
more qBEG parameters to like qEEG parameters obtained 
from at least one healthy normal individual; then comparing 
the one or more deviations to deviations detected in a sample 
population of known fibromyalgia patients. 
0104 Clean EEG records from a subject may be math 
ematically analyzed for various time domain and frequency 
domain parameters of their electrical signals, consistent with 
analysis techniques already described, and then findings from 
these mathematical analyses may be statistically compared to 
like parameters taken from an age and gender matched data 
base of healthy normal individuals or individuals known to 
have fibromyalgia. The statistical comparisons may include, 
but are not limited to deviations from a standard normal 
distribution of like EEG measures associated with members 
of a database of healthy normal individuals or individuals 
known to have fibromyalgia. The results of those compari 
Sons may then be presented in a graphical or numerical format 
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for analysis by a competent health care professional or person 
of similar expertise for the existence of statistically signifi 
cant abnormal deviations, or the lack thereof. A finding in 
Support of a fibromyalgia diagnosis would be supported if 
there is an absence of any significant deviation between mea 
sures from a subject’s clean EEG and those from a database 
comprising individuals known to have fibromyalgia. 
0105 Analyses of clean EEG from a subject may be sta 
tistically correlated to measures of symptom severity. As 
previously described, analysis findings may be mathemati 
cally analyzed for various time domain and frequency domain 
parameters of electrical signals. A number of measures of the 
magnitude of deviation from standard normal distributions of 
either healthy normal EEG or known fibromyalgia patient 
EEG can be determined. The magnitudes may be presumed to 
be related to the severity of the condition and may be statis 
tically correlated to such symptom measures that may 
include, but are not limited to, tender point pain pressure 
thresholds as determined by an algometer, and various other 
indices of pain derived from the algometry measures (e.g. the 
Sum of all 18 tender point pain tolerance measures, the aver 
age of all 18 tenderpoint pain tolerance measures, etc.). Such 
analysis has utility in both predicting symptom severity in 
individuals with fibromyalgia, and in determining the effect 
of therapeutic intervention to corrector manage symptoms of 
fibromyalgia. 
0106 EEG analyses may also be used for determining the 
location of abnormal brain activity and further for determin 
ing points for application of neuromodulation. 
0107 Treatment may include the application of a nonin 
vasive neuromodulation signal in a manner designed to cor 
rect abnormalbrainfunction identified inaccordance with the 
aforementioned EEG analyses. Suitable noninvasive neuro 
modulation techniques are disclosed in applicant's U.S. 
patent application Ser. No. 1 1/490.255 (issued as U.S. Pat. 
No. 7,715,910) and applicant’s International Patent Applica 
tion Ser. No. PCT/US2008/72395, which are incorporated 
herein by reference. The noninvasive neuromodulation signal 
may comprise those waveforms designed to minimize tissue 
impedance, such as an “amplitude modulated pulse width 
modulated” (AMPWM) signal. An AMPWM signal utilizes a 
high frequency carrier signal that is amplitude modulated by 
a low frequency neuromodulation signal. The carrier signal is 
of sufficiently high frequency so as to be less attenuated by the 
impedance of tissues due to their capacitive reactance. The 
frequencies used in the neuromodulation signal are lower 
than the frequency of the carrier signal, and are chosen to 
provide therapeutic benefit. By using the neuromodulation 
signal to amplitude modulate the carrier signal, and Subse 
quently applying the combined signal to tissues, the neuro 
modulation signal is less attenuated by the impedance of the 
tissue permitting greater penetration of electrical current and 
field. The carrier signal is further pulse width modulated in an 
AMPWM signal to control the time averaged current, and 
hence the power of the signal delivered to the tissues. An 
apparatus for generating and delivering an AMPWM signal 
includes any number of electric signal generating devices 
capable of generating and altering the parameter aspects of an 
AMPWM signal. Various forms of an AMPWM signal and 
apparatus for generating an AMPWM signal are disclosed in 
the applicant's U.S. application Ser. No. 1 1/490,255 (issued 
as U.S. Pat. No. 7,715,910) and applicant’s International 
Patent Application Ser. No. PCT/US08/72395. Reports on the 
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results of a double-blind, placebo-controlled study of the 
efficacy of this treatment are summarized below: 
0108. Thirty-nine (39) active treatment (AT) fibromyalgia 
patients and 38 comparable placebo control patients com 
pleted non-invasive neuromodulation treatment, applied 
twice a week for 11 weeks. The placebo condition (PL) was 
created by not delivering the non-invasive neuromodulation 
signal. Both number of tender point (defined by the American 
College of Rheumatology) and total pain score were evalu 
ated at baseline and end of treatment. Subjects also completed 
health impact questionnaires (Fibromyalgia Impact Ques 
tionnaire FIQ, Symptom CheckList-90 ISCL-90. Beck 
Depression Inventory (BDI), and sleep quality) at baseline 
and end of treatment period, and FIQS in long-term follow up. 
Primary outcome measures were changes in the number of 
tender points (TePs) and level of TeP pain, secondary mea 
Sures were changes in the questionnaire responses. 
0109 Analysis of results showed AT patients improved in 
number of positive TePs, mean 17.4 pre-treatment to 9.9 
post-treatment (P<0.001). The between group change was 
significantly improved (PL -0.2 versus AT-7.4, P-0.001). 
Sixty-two percent (62%) of the AT group no longer met the 
tender point criteria for FM classification following treat 
ment. Similarly, the tenderpoint score (TPS) for the AT group 
improved from 36.7 to 56.4 (P<0.001) whereas the control 
group got slightly worse, 38.9 to 35.8. The between group 
change was also significantly improved (PL -3.2 Versus 
AT+19.6, P<0.001). The total FIQ score in the AT group 
improved from 65.1 to 46.0 (P<0.001). In other measures, the 
AT group reported 61.8% improvement in sleep quality (P<0. 
001). Long term follow-up FIQ analysis was done at an aver 
age of 16.8 months since discontinuation of treatment (range 
12-28 months). There was a continuing long term improve 
ment over baseline values (P<0.001). There were no signifi 
cant side effects. 
0110 Mitigation of abnormal activity is accomplished by 
generating and applying to the Subject an electrical stimula 
tion signal having at least one parameter configured to modu 
late at least one abnormal aspect of the subject's EEG, which 
corresponds to at least one statistically significant difference 
found in the statistical comparison of qEEGs. Such abnormal 
aspects of the subject's EEG may include, but are not limited 
to, abnormally high or low amplitudes, abnormal amplitudes 
in specific frequencies or frequency segments, abnormal 
spectral power, abnormal relative power, amplitude asymme 
try, and abnormally high or low coherence. The application of 
said electrical stimulation signal, preferably an AMPWM 
noninvasive neuromodulation signal, may comprise a first 
step of choosing neuromodulation signal parameters 
intended to correct abnormal brain function identified in 
accordance with the aforementioned EEG analyses. These 
parameters may include, but are not limited to, a choice of the 
carrier signal frequency, neuromodulation signal frequency, 
amplitude, waveform, duty cycle, application times, and 
phase. The step of choosing neuromodulation signal param 
eters may include identifying a particular signal parameter, 
Such as a frequency from a patient's EEG, that is statistically 
different than normal, e.g., an EEG frequency that is lower 
than normal at a particular location. The chosen neuromodu 
lation signal parameters may thus, for example, include a 
frequency generally equal to that of the abnormally low mea 
Sured EEG frequency. The step of choosing neuromodulation 
signal parameters may alternatively or additionally include 
identifying an area of the brain where the spectral amplitude 
May 21, 2015 
of an EEG frequency measure is found to be statistically 
different than normal. This step may further include identi 
fying the direction and magnitude of said spectral amplitude 
deviation from normal for said statistically different than 
normal EEG frequency measure. The identifying step may 
yet further include choosing signal parameters that include 
frequencies ranging between the frequency of the statistically 
different than normal measure (F1) and a frequency that is (a) 
within an approximate range of from 20 Hertz greater than F1 
to F1 for the case in which the direction of deviation for F1 is 
less than normal; or (b) within an approximate range of from 
20 Hertz less than F1 to F1 for the case in which the direction 
of deviation for F1 is greater than normal. The identifying 
step may further include choosing signal amplitudes and 
application times that are proportional to the magnitude of 
deviation from normal for said statistically different than 
normal EEG frequency measure. The identifying step may 
further include choosing signal duty cycle so as to provide a 
signal that cannot be felt by a person when applied. The 
identifying step may further include choosing a signal wave 
form that encompasses at least one of the frequencies in the 
range of F1 plus or minus 20 Hertz. The identifying step may 
also include applying at least two neuromodulation signals to 
different areas of the brain, and applying a phase shift 
between the at least two signals where the phase shift may 
range between Zero and 180 degrees. 
0111. The application of a noninvasive neuromodulation 
signal may further comprise the step of choosing neuromodu 
lation signal application location to provide for application of 
neuromodulation to tissues corresponding to one or more of 
the spatial location(s) of abnormal brain function identified 
by the aforementioned analyses. Signal application may fur 
ther include the use of electrodes to create a signal path 
between an electrical stimulation signal source Such as an 
apparatus for generating an AMPWM signal and a stimulat 
ing electrode positioned proximate to brain tissues in at least 
one area of abnormal brain activity, either invasively or non 
invasively. 
0112 Delivery of the neuromodulation signal may be 
accomplished by utilizing an electrode set comprising inva 
sive stimulating electrodes positioned on or in near proximity 
to brain tissues exhibiting abnormal function, i.e., within 
approximately 20 mm. The electrode set may further com 
prise an invasive ground electrode positioned Such that a 
vector path between stimulating electrodes and a ground elec 
trode passes through tissues to be stimulated. 
0113 Delivery of the neuromodulation signal may be 
accomplished by utilizing an electrode set comprising one or 
more non-invasive stimulating electrodes adapted to be worn 
by a subject such that the stimulating electrodes rest on the 
Scalp in proximity to brain tissues exhibiting abnormal func 
tion. The electrode set may further comprise a non-invasive 
ground electrode adapted to be worn by a subject such that the 
non-invasive ground electrode rests on the scalp in proximity 
to brain tissues exhibiting abnormalfunction; positioned Such 
that a vector path between non-invasive stimulating elec 
trodes and a non-invasive ground electrode passes through or 
in near proximity to tissues to be stimulated. 
0114 Delivery of the neuromodulation signal may be 
accomplished by utilizing an electrode set comprising one or 
more non-invasive stimulating electrodes adapted to be worn 
by a subject such that the stimulating electrodes rest on the 
skin posterior to the cervical vertebrae and in proximity to the 
vagus nerve. The electrode set may further comprise a non 
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invasive ground electrode adapted to be worn by a subject 
Such that the non-invasive ground electrode rests on the scalp 
in proximity to brain tissues exhibiting abnormal function; 
positioned Such that a vector path between non-invasive 
stimulating electrodes and a non-invasive ground electrode 
passes through or in near proximity to tissues to be stimu 
lated. 
0115 The period of time over which therapeutic interven 
tion takes place may comprise repeated application of a neu 
romodulation signal for finite duration, with rest time taking 
place between applications, and total number of applications 
comprising a finite number. The finite duration may be 
between one second and 60 minutes; the rest time may be 
between one minute and seven days; and the total number of 
applications may be between one application and 300 appli 
cations. The number of applications may be proportional to 
either the extent of abnormal function and/or the time that the 
abnormal function has been present. 
0116. The method of generating described neuromodula 
tion signals may include the use of an apparatus such as that 
disclosed in the applicant's U.S. patent application Ser. No. 
1 1/490,255 (issued as U.S. Pat. No. 7,715,910), which is 
assigned to the assignee of the present application and incor 
porated herein by reference. 
0117 The method may include the steps of repeating 
quantitative assessments such as EEG testing, TPP testing 
and statistical analysis on a subject, as described herein, fol 
lowing a period of therapeutic intervention on said Subject. 
The method may further comprise statistical comparison of 
parameters of the repeated Statistical analysis to like param 
eters of the statistical analysis of the subject done before the 
previous therapeutic intervention was started. Such compari 
son might include, but is not limited to, paired t-testing sta 
tistics, correlation analysis of changes in Symptom severity, 
and Subsequent comparison to a database of age and gender 
matched healthy normal individuals or individuals suffering 
from a brain related chronic pain condition Such as fibromy 
algia. These comparisons may be used to assess the effective 
ness of the therapeutic intervention, in particular noninvasive 
neuromodulation, or to determine if an alternate intervention 
is indicated in the absence of treatment effect from a current 
therapeutic intervention. The comparisons could also be used 
to determine if further therapeutic intervention is indicated in 
the absence of any abnormal findings. The comparisons may 
further be used to modify neuromodulation signal parameters 
in accordance with the findings of the repeated quantitative 
assessment step. 
0118 With specific reference to the TPP test, repeat test 
ing may include the application of tender point pressure 
using, e.g., an algometer, only to the levels required to cause 
a painful response recorded in the same testing performed 
before therapeutic intervention. 
0119 Further according to the method, EEG data may be 
acquired at a first location (e.g. a clinical location) and the 
acquired EEG data transferred via electronic means to 
another location (e.g. a central analysis location) for the 
herein described analysis and statistical comparisons to be 
accomplished. The electronic means of data transfer may 
include, but isn't limited to means of data transfer across a 
local area network and/or the Internet. Consequently, analysis 
and Statistical findings may then be transferred from a central 
analysis location to a clinical location, where they may be 
used in various ways by a physician or similarly qualified 
health care professional for the determination of parameters 
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of a neuromodulation signal used for therapeutic intervention 
and treatment of fibromyalgia. 
I0120) Further according to the method, EEG data may be 
acquired at a first location (e.g. a clinical location) and the 
acquired EEG data transferred via electronic means to 
another location (e.g. a central analysis location) for a pur 
pose such as increasing the size of various databases of indi 
viduals known to be suffering from fibromyalgia, individuals 
known to be suffering from a chronic pain condition that is not 
fibromyalgia, and healthy normal individuals. 
I0121 Further according to the method, neuromodulation 
signal parameters may be determined at a central analysis 
location and Subsequently transferred as data via electronic 
means to an apparatus at another location (e.g. a clinical 
location) provided for delivery of a neuromodulation signal 
used for therapeutic intervention and treatment of fibromyal 
gia. The electronic means of data transfer may include, but 
isn't limited to, means of data transfer across a local area 
network and/or the Internet. 
0.122 The steps of application of the neuromodulation 
signal and repeat measurements and analyses of a subjects 
EEG may be continued until abnormal brain function, as 
determined by, for example, EEG analysis, is modulated and/ 
or mitigation or resolution of symptoms of the chronic pain 
condition (such as fibromyalgia) are achieved. 
I0123. Alternatively, non-EEG methods of assessing brain 
function may be utilized to quantify and locate abnormal 
brain function. Such methods include, but are not limited to 
positron-emission tomography (PET) scans, magnetic reso 
nance imaging (MRI) testing and single photon emission 
computed tomography (SPECT) scans. 
0.124. Alternatively, EEG data may be collected during a 
therapeutic intervention that includes application of an elec 
trical stimulation signal Such as a neuromodulation signal, 
and that EEG data may be analyzed by real-time computa 
tional algorithms such as Fast Fourier Transforms (FFT) to 
determine various statistics associated with EEG, including 
but not limited to spectral amplitudes offrequencies compris 
ing said EEG. The statistics may be used to modify param 
eters of a neuromodulation signal for the purposes of opti 
mizing therapeutic benefit. In a preferred embodiment, EEG 
data collected during a therapeutic neuromodulation signal 
application is analyzed for spectral components using an FFT 
algorithm. A comparison between the frequency of a stimu 
lation signal and the highest spectral amplitude of measured 
EEG signal is made. If said comparison finds these frequen 
cies to be the same, then a corresponding modification to the 
neuromodulation signals frequency would be made. 
0.125. As shown in FIG. 2, the abnormal brain function 
diagnostic and treatment apparatus 100 may include a com 
puter 101 interfaced to a signal generation and interface mod 
ule 121 utilizing any number of methods known in the art such 
as the use of a computer interface cable 102. Any power 
source 103 known in the art to sufficiently provide power to 
computers and electronic devices may be utilized and exter 
nally interfaced with power wires 104. The signal generation 
and interface module 121 may include a microcontroller 106 
electronically coupled to a signal generator circuit 107, to an 
EEG acquisition circuit 108 and to any number of device 
interface circuits 109. All external interfaces may utilize con 
nectors 105 commonly known in the art. All electrical and 
electronic coupling methods may utilize conductors 112 
known in the art. 
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0126. In practice, the computer 101 may be configured to 
communicate via interface to the microcontroller 106 for 
various purposes including the transfer of AMPWM signal 
parameters and the receipt of EEG data. The computer 101 
may include a user interface that allows an operator to moni 
tor and/or influence operation of the diagnostic and treatment 
apparatus 100. 
0127. A neuromodulation signal such as an AMPWM sig 
nal may be generated in the signal generator circuit 107 and 
delivered to a stimulation signal interface 110 that includes 
connectors 105. As shown in FIG. 3, the signal generator 
circuit 107 may comprise a biopotential amplifier 114 that 
measures EEG signals and may be operatively coupled to any 
number of filter 115 circuits configured to reduce extraneous 
electrical noise in an EEG signal. The biopotential amplifier 
114 may be further operatively coupled to an isolation ampli 
fier 116 for human subject protection, and to a microcontrol 
ler 106 through an analog-to-digital interface 117. In opera 
tion, EEG may be acquired through a stimulation signal 
interface comprising electrical conductors 5 interfaced at 
connectors 105. The acquired EEG may be conducted to a 
biopotential amplifier 114, filter circuits 115, isolation ampli 
fier 116 and to a microcontroller 106 for use such as, but not 
limited to, in software executed by an interfaced computer 
101 for generating and delivering an AMPWM signal. The 
signal generator circuit 107 may further comprise an isolated 
power supply 118 configured to provide circuit power and 
provide human Subject protection, a Switching transistor 119 
that has base connection to a digital-to-analog interface 122 
on a microcontroller 106, and an inductor 120 configured and 
positioned to induce an electrical stimulation signal Such as 
an AMPWM signal into a conductor 112 leading to a connec 
tor 105 and electrical conductor 5 in a stimulation signal 
interface. In operation, the microcontroller 106 may generate 
a stimulation signal and conduct that signal via a digital-to 
analog interface 122 to the base of the Switching transistor 
119. Electrical power from an isolated power supply 118 may 
then switched on and off through the switching transistor 119 
creating an amplified Stimulation signal in accordance with 
the stimulation signal waveform generated by the microcon 
troller 106. The amplified stimulation signal may be further 
conducted to an inductor 120, and further induced into a 
conductor 112 creating a therapy stimulation signal in the 
conductor 112. The therapy stimulation signal may then be 
delivered to a human subject via the conductor 112 to a 
stimulation signal interface comprising electrical conductors 
5 interfaced at connectors 105. In other words, the neuro 
modulation signal may be applied using an apparatus com 
prising a microcontroller 106 configured to generate signal 
waveforms and coupled to a signal generator circuit 107 
configured to transform the signal waveforms into desired 
AMPWM neuromodulation signals. The signal generator cir 
cuit 107 may comprise circuit elements such as a biopotential 
amplifier 114 configured to measure EEG signals, a filter 
circuit 115 configured to reduce electrical noise in EEG sig 
nals, an isolation amplifier 116 configured to protect human 
Subjects, an analog-to-digital interface 117 configured to con 
Vert analog EEG signals to digital signals, an isolated power 
Supply 118 configured to provide circuit power and human 
Subject protection, a Switching transistor 119 configured to 
generate an amplified stimulation signal by Switching on and 
off electrical power from the isolated power supply in 
response to stimulation signals received at a base of the 
Switching transistor from the microcontroller, and an inductor 
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120 configured to induce an electrical stimulation signal into 
a conductor 112. Additional forms of an AMPWM signal and 
apparatus for generating an AMPWM signal are disclosed in 
the applicant's U.S. patent application Ser. No. 1 1/490,255 
(issued as U.S. Pat. No. 7,715,910), which is incorporated 
herein by reference in its entirety. 
I0128. As shown in FIG.4, the apparatus 100 may include 
a cap 3 configured to be worn on a subjects head in a prede 
termined orientation. At least two electrodes 1, 2, which may 
be non-invasive type electrodes, may be carried by the cap. 
One of the electrodes 1 may be configured to act as a stimu 
lating electrode 1 for delivering a neuromodulation signal to 
the subject’s head 4, and the other of the electrodes 2 may be 
configured to act as a ground electrode and to receive neuro 
modulation signals transmitted by the signal delivery elec 
trode 1. The cap 3 may be of any suitable configuration to 
include a skull-cap configuration as shown in the drawings, or 
may simply comprise flexible bands. In any case, the cap 3 is 
adapted to carry the electrodes 1, 2 and to be worn on the head 
4 during mitigation of abnormal brain activity, and, more 
particularly, to facilitate non-invasive neuromodulation sig 
nal delivery to a subject’s brain. 
I0129. EEG from a subject may be collected through the 
EEG acquisition circuit 108, which may include any form of 
EEG amplifier instrument known in the art, through an EEG 
interface 111 that may include connectors 105. At least one 
additional electrode 16 may be carried by the cap 3 and 
positioned to sense and transmit EEG signals to the EEG 
acquisition circuit 108. Alternatively, a stimulating electrode 
1 may also serve as an EEG sensor. In other words, one or 
more stimulating electrodes 1 may be coupled to the EEG 
acquisition circuit 108 and configured to sense and transmit 
EEG signals to the EEG acquisition circuit 108. The cap 3 
may also carry electrical conductors 5 that provide signal 
paths between an electrical stimulation signal source Such as 
the signal generator circuit 107 of the diagnostic and treat 
ment apparatus 100 and stimulating electrodes 1 and ground 
electrodes 2; and the electrical conductors 5 may also provide 
signal paths between an EEG acquisition circuit 108 and 
additional electrodes 16, whereby the conductors may elec 
trically couple to connectors 105 at a stimulation signal inter 
face 110 and an EEG interface 111 of a diagnostic and treat 
ment apparatus 100. The stimulating electrodes 1 and ground 
electrodes 2 may be permanently or removably affixed into 
the cap 3 in cap locations where, when the cap 3 is placed on 
a subject's head 4 in a predetermined orientation, the stimu 
lating electrodes 1 and ground electrodes 2 are positioned 
proximate to respective areas 11 of brain tissues to be stimu 
lated, e.g., areas of brain tissue associated with abnormal 
brain activity. 
0.130. The electrodes 1, 2 may be permanently or remov 
ably Supported in cap locations on the cap 3 so that, when the 
cap is worn on a Subjects head in a predetermined orienta 
tion, a vector path 12 extending between the stimulating 
electrode 1 and the ground electrode 2 passes through the 
desired area 11 of brain tissues to be stimulated. Further, the 
cap 3 may be sized in various ways to fit or to be adjustable to 
a variety of sizes and shapes of human heads 4 and to carry 
any number of stimulating electrodes 1 and ground electrodes 
2 in cap locations that will cause neuromodulation signals to 
pass along vector paths 12 through predetermined locations 
of abnormal brain activity 11 in a subject’s brain 10. The 
electrodes 1, 2 may Subsequently be removed and placed in 
new cap locations that will cause neuromodulation signals to 
US 2015/O 141529 A1 
pass along vector paths 12 through predetermined locations 
of abnormal brain activity 11 in a second subject’s brain 10. 
0131 The cap 3 may be configured to carry any number of 
electrical circuits known in the art for storing information. As 
shown in FIG. 5, such circuit may include a radio frequency 
identification (RFID) chip 7 incorporated into a cap 3 and 
utilized to store information including, but not limited to, the 
identification of the subject the cap is intended to be used on, 
dates and times of use, parameters of an electrical stimulation 
signal to be used in association with the cap and delivery of 
non-invasive neuromodulation, a total number of times the 
cap has been used and monitoring data associated with qual 
ity of use. 
0132) The diagnostic and treatment apparatus 100 may 
include any number of external devices that may be utilized in 
the process of providing assessment, diagnostics, or therapy 
and that may be coupled to the device interface circuit 109 and 
interfaced through a device interface 113 that may include 
connectors 105. For example, the apparatus 100 may include 
an RFID reader 14 for establishing electrical connectivity 
between the microcontroller 106 and the RFID chip 7 through 
a device interface 113. The use of an RFID reader 14 and 
RFID chip 7 creates a radio frequency pathway 13 that allows 
information incorporated into the RFID chip 7 to be accessed 
and utilized by software executed by the microcontroller 106 
and/or an interfaced computer 101. 
0133. As shown in the embodiment illustrated in FIG. 6, as 
an alternative to the use of an RFID chip 7, other suitable 
methods known in the art for accessing information stored in 
electrical circuits may be used, such as methods that use 
direct electrical connections via conductors such as wires 8. 
Such methods may include the use of any number of program 
mable memory circuits 9 connected via wires 8 to a memory 
circuit programmer 15, which may be further interfaced to the 
microcontroller 106 and/or the computer 101 through the 
device interface 113, such that information incorporated into 
the programmable memory circuit 9 may be accessed and 
utilized by the microcontroller 106 and/or the computer 101 
via, for example, software executed by the computer 101. 
0134. Alternatively, neuromodulation may be used as a 
method of treatment for fibromyalgia in combination with 
treatment of other coexisting physical conditions that may or 
may not be associated with fibromyalgia. In addition, or alter 
natively, neuromodulation may be used as a method of treat 
ment in combination with otherforms of treatment utilized to 
affect symptoms of fibromyalgia. 
0135 With reference to FIGS. 11-23, a method is also 
provided for alleviating centralized pain such as that arising 
from an abnormal brain condition that may include, but is not 
limited to, central sensitivity and abnormal network connec 
tivity involved in pain processing. The method may include 
assessing the brain of a subject Suffering from pain, diagnos 
ing abnormal brain conditions associated with centralized 
pain, locating at least one area of abnormal brain measure 
associated with an abnormal brain condition producing the 
centralized pain and alleviating the centralized pain by apply 
ing cortical stimulation to alter the abnormal brain condition. 
The step of applying cortical stimulation includes, but is not 
limited to, the application of a cortical stimulation signal to 
tissues corresponding to the at least one area of abnormal 
brain measure. Preferably, the cortical stimulation signal 
comprises waveforms configured to minimize tissue imped 
ance while effecting noninvasive cortical stimulation. Treat 
ment effect is realized when one or more abnormal brain 
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conditions corresponding to the at least one area of abnormal 
brain measure and associated with or producing the central 
ized pain, have been alleviated. 
0.136 The step of assessing the brain of a subject suffering 
from pain includes, but is not limited to, making measures of 
a brain condition, e.g., of a brain function, brain activities or 
brain anatomy, either by direct assessment techniques known 
in the art Such as neuroimaging, or by indirect assessment 
Such as analysis of other biological measures. The assessment 
step includes use of any method known in the art to determine 
the presence of centralized pain in a subject, including meth 
ods known to identify abnormal brain conditions associated 
with centralized pain including, but not limited to, central 
sensitivity or abnormal levels of network connectivity. The 
diagnosing step may include making measures to Support a 
determination of the presence of one or more brain conditions 
associated with centralized pain in a subject, including, but 
not limited to, central sensitivity or abnormal levels of net 
work connectivity. The locating step may include making 
measures to identify at least one target region of the Subjects 
brain that may be involved in centralized pain in a Subject, 
including, but not limited to, regions involved in central sen 
sitivity or exhibiting abnormal levels of network connectivity, 
or regions where abnormal brain conditions associated with 
centralized pain, Such as central sensitivity or abnormal levels 
of network connectivity, originate. One skilled in the art of 
medical assessment may administer and interpret one or more 
assessments designed to detect centralized pain. Such assess 
ments may include any one or more known neuroimaging 
tests. Such assessments may also be used for detecting the 
presence and identifying the location of one or more abnor 
mal brain conditions through interpretation. 
0.137 In a preferred embodiment, a means of assessing a 
brain to determine the presence of centralized pain in a Sub ject includes the use of one or more neuroimaging tests uti 
lizing methods and apparatuses known in the art, with the 
neuroimaging test being performed before, during and after 
the application of any one or more forms of sensory stimula 
tion (SS) intended to cause a brain response to the SS. This 
test is henceforth referred to as a “brain response test' (BRT), 
and the SS includes any noxious, pain inducing or non-pain 
ful means. In a preferred embodiment, a BRT may include an 
electroencephalogram (EEG) test performed with eyes closed 
or eyes open, with at least one additional EEG record made 
that includes EEG data obtained during and after the appli 
cation of any one or more forms of an SS. 
0.138. One embodiment of an SS is palpation of tender 
points on the subject’s body, consistent with the method 
described herein as a tender point test. Other means of caus 
ing a painful or noxious SS for the purposes of a BRT may 
include, but are not limited to, application of mechanical 
pressure on any part of the body, application of otherforms of 
mechanical stimulation to any part of the body (e.g. a 
"pinch'), application of an electrical stimulus, application of 
aheat-producing stimulus, and in vivo or in vitro introduction 
of a chemical agent meant to elicit a painful or non-painful 
response. Means of causing a non-painful SS for the purposes 
of a BRT may include, but are not limited to, forms of typi 
cally non-painful physical contact including mechanical 
brushing, controlled physical movements made by the Sub ject, and various forms of mental processing Such as cognitive 
exercises. 
0.139. Further to the application of an SS, the method 
includes any number of applications of stimulation to elicit 
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any number of brain responses. For example, a single SS may 
be applied to produce a single brain response. Alternately, a 
series of SS applications may be made over a period of time to 
produce multiple brain responses so that a BRT may include 
assessing changes in brain response over time. Such series of 
PS applications may include one or more applications of any 
combination of noxious, painful or non-painful stimuli, with 
a period of rest between each application ranging from one 
second to several minutes. Such assessment of changes in 
brain response may include, but are not limited to, quantifi 
cation of temporal Summation of pain, also known in the pain 
literature as “wind up'. 
0140. The BRT test may be executed by acquiring a brain 
response record using any means of neuroimaging test. In a 
preferred embodiment, a brain response test EEG (“BRT 
EEG') record is obtained that includes EEG data obtained for 
a period of time before, during, and after the application of 
any number of an SS. EEG data may be obtained from EEG 
electrode sites for a period of time, preferably ranging from 
one second to 15 minutes, prior to commencement of a first 
SS. During application of an SS, EEG data obtained may be 
denoted as EEG collected during application of the SS. Data 
collected during application of an SS may have unwanted 
aspects. For example, EEG data collected during the applica 
tion of an SS may also contain measurements of electromyo 
graphic signals arising from muscle contractions a patient 
may make as a result of feeling a sensation Such as pain. 
Accordingly, the data collected during the application of an 
SS may or may not be removed in Subsequent analysis 
according to the method. Further to the embodiment, EEG 
data may be obtained from EEG electrode sites for a period of 
time, preferably ranging from one to 15 minutes, after appli 
cation of an SS. 
0141 Further to the BRT test method, a record is made 
quantifying parameters associated with the one or more SS 
being used. For example, if an SS involves palpation of a 
tender point, then the location and amount of mechanical 
pressure being applied at or near the time the Subject reports 
a painful sensation may be recorded. Other examples of quan 
tification of an SS may include, but are not limited to, the 
amount of pressure on any body part required to elicit pain, 
parameters of other forms of mechanical stimuli, parameters 
of forms of electrical stimuli, parameters of forms of heat 
stimuli, parameters of an introduced chemical agent, param 
eters of brush strokes and parameters of a mental exercise. 
0142 Further to the BRT test method, the recording of 
EEG may continue for a period of time after completion of 
each of the one more SS applications, with the period of time 
preferably being between one second and 15 minutes. The 
process of application of an SS and Subsequent recording of 
EEG may be repeated until all intended applications of an SS 
are completed. Accordingly, the resulting EEG data record 
includes the BRT EEG records for all applications of SS. 
0143. The BRT EEG records may be acquired for a period 
of time that is sufficient to extract from each BRT EEG record 
a record of “clean EEG data, that is, EEG data that have 
minimal non-EEG signals such as extraneous electrical noise 
arising from, for example, instrumentation anomalies or elec 
tromyographic movement. Preferably, a record of clean EEG 
data is sufficient to provide enough EEG data to performany 
one of a number of EEG analyses known in the art with a 
sufficiently high degree of statistical confidence. More pref 
erably, all EEG records according to the method may be 
individually edited to provide from each EEG record a period 
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comprising a minimum of 60 seconds of clean EEG. With 
regard to the BRT test method, clean data preferably does not 
include any EEG data acquired during the application of an 
SS. 
0144. Further to the BRT test method, and in the preferred 
embodiment, clean EEG records may be then mathematically 
analyzed for various time domain and frequency domain 
parameters of their respective electrical signals. These analy 
ses may include, but are not limited to Voltage analysis, cur 
rent analysis, Voltage and current analysis, frequency spec 
trum analysis using Fast Fourier Transform (FFT) analysis, 
frequency spectrum analysis using a wavelet analysis 
method, frequency spectrum analysis using absolute power 
analysis method, frequency spectrum analysis using relative 
power analysis method, frequency spectrum analysis using 
phase analysis method, frequency spectrum analysis using 
coherence analysis method, frequency spectrum analysis 
using amplitude symmetry analysis method, phase analysis, 
various forms of network analysis and source localization of 
electrical activity in the brain using inverse EEG computation 
analysis. The purpose of Such analyses is to determine the 
presence of one or more abnormal brain conditions, e.g., 
brain function, brain activity, brain anatomy or related brain 
measures that indicate centralized pain such as, but not lim 
ited to, central sensitivity and abnormal levels of network 
connectivity. 
0145 According to the BRT test method, a finding of 
centralized pain is made by analyzing findings from the afore 
mentioned BRT analyses. Such findings may include, but are 
not limited to, a determination of a brain condition associated 
with central sensitivity or abnormal brain network connectiv 
ity associated with pain processing. In a preferred embodi 
ment, BRT EEG records may be statistically compared to the 
same parameters determined from EEG records taken from 
age and gender matched databases of either healthy normal 
individuals or individuals that are suffering from pain that is 
not centralized pain. Such statistical analyses may include, 
but are not limited to deviations from a standard normal 
distribution. Findings of statistically significant abnormal 
deviation, or lack thereof, may then be presented in a graphi 
cal or numerical format for analysis by a competent health 
care professional or person of similar expertise. 
0146 EEG abnormalities consistent with subjects suffer 
ing from centralized pain may include, but are not limited to 
one or more of the following: (1) abnormal levels of in EEG 
power in spectral segments of resting EEG measures, includ 
ing but not limited to, an abnormal level of EEG power across 
the entire resting EEG spectra; (2) abnormal levels of coher 
ence or phase shift between at least two resting EEG sites; (3) 
abnormal levels of resting EEG relative power in particular 
regions of the brain. 
0147 Further EEG abnormalities consistent with subjects 
Suffering from centralized pain, and drawn particularly to the 
EEG BRT test method, may include but are not limited to a 
finding of (1) statistically significant increases in EEG abso 
lute power, particularly in the alpha and beta segments, in the 
parietal, occipital, and temporal areas of the brain as com 
pared to the resting EEG record for the same subject; or (2) 
statistically significant increases in coherence in spectral seg 
ments of the BRTEEG record as compared to the resting EEG 
record for the same subject. 
0.148. A determination of centralized pain may be made 
when physical assessment findings that Support a diagnosis of 
centralized pain are augmented by assessing a brain following 
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a BRT. The assessment of a BRT may include a statistical 
comparison between any one or more of the subjects BRT 
measures and a database of like BRT measures of either 
healthy normal individuals, individuals suffering from pain 
that is not centralized pain, or individuals suffering from 
centralized pain. Alternately, centralized pain may be diag 
nosed by Statistically determining one or more deviations 
between a subjects one or more BRT measures and like BRT 
measures obtained from at least one healthy normal indi 
vidual or at least one individual Suffering from pain that is not 
centralized pain; then comparing the one or more deviations 
to like deviations detected in a sample population of Subjects 
known to be suffering from centralized pain. 
0149. In a preferred embodiment, clean resting EEG or 
BRT EEG records from a subject may be mathematically 
analyzed for various time domain and frequency domain 
parameters of their electrical signals, consistent with analysis 
techniques already described, and then findings from these 
mathematical analyses may be statistically compared to like 
parameters taken from age and gender matched databases of 
either healthy normal individuals, individuals suffering from 
pain that is not centralized pain, or individuals known to be 
Suffering from centralized pain. The statistical comparisons 
may include, but are not limited to deviations from a standard 
normal distribution of like EEG measures associated with 
members of databases of healthy normal individuals, indi 
viduals Suffering from pain that is not centralized pain, or 
individuals known to be suffering from centralized pain. The 
results of those comparisons may then be presented in a 
graphical or numerical format for analysis by a competent 
health care professional or person of similar expertise for the 
existence of statistically significant abnormal deviations, or 
the lack thereof. A centralized pain diagnosis would be Sup 
ported if one or more findings of either resting EEG or BRT 
EEG records are consistent with like findings from a database 
comprising individuals known to be suffering from central 
ized pain. More preferably, a centralized pain diagnosis 
would be supported if one or more findings of either resting 
EEG or BRT EEG records are consistent with statistical sig 
nificance to like findings from a database comprising indi 
viduals known to be suffering from centralized pain. 
0150. Further according to the BRT test method, measures 
of an abnormal brain condition, e.g., brain function, brain 
activity, brain anatomy or related brain measures arising from 
analyses of BRT test findings from a subject may be corre 
lated to measures of symptom severity, Such as but not limited 
to pain severity. Such correlation has utility in both predicting 
symptom severity in individuals with centralized pain, and in 
determining the effect of therapeutic intervention to alleviate 
symptoms of centralized pain. 
0151. Further, BRT test analyses according to the method 
may also be used for determining the location of an abnormal 
brain condition and further for determining points for appli 
cation of cortical stimulation according to the method recited 
herein for alleviating centralized pain. 
0152 Alleviation of centralized pain, including but not 
limited to central sensitivity and abnormal brain network 
connectivity associated with centralized pain, may include 
the application of various forms of cortical stimulation in a 
manner designed to alleviate the abnormal brain condition 
identified in accordance with the aforementioned BRT test 
method and analyses. Although any form of cortical stimula 
tion is included in the method, a preferred embodiment 
includes noninvasive neuromodulation techniques, and more 
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preferably includes use of an AMPWM signal form as dis 
closed in applicant's U.S. patent application Ser. No. 1 1/490, 
255, which has issued as U.S. Pat. No. 7,715,910 and which 
is attached as Appendix A, and applicant’s International 
Patent Application Ser. No. PCT/US2008/72395 all of which 
are incorporated herein by reference. 
0153. Alleviation of one or more abnormal brain condi 
tions associated with centralized pain may be accomplished 
by generating and applying to the Subject a cortical stimula 
tion signal having at least one parameter configured to modu 
late at least one abnormal brain measure that is associated 
with one or more abnormal brain conditions associated with 
centralized pain, and that corresponds to at least one statisti 
cally significant difference finding of a BRT test method. 
Although any form of cortical stimulation is included in the 
method, a preferred embodiment includes noninvasive neu 
romodulation techniques, and more preferably includes use 
of an AMPWM signal form as disclosed in applicant's U.S. 
Pat. No. 7,715,910, which is attached as Appendix A, and 
applicant’s International Patent Application Ser. No. PCT/ 
US2008/72395, which are incorporated herein by reference. 
0154 The method may include the steps of repeating one 
or more analyses in accordance with the BRT test method, as 
described herein, following a period of therapeutic interven 
tion on a Subject. The method may further comprise statistical 
comparison of parameters of the repeated analyses to like 
parameters of the analyses of the subject's BRT measures 
done before the period of therapeutic intervention was 
started. These comparisons may be used to assess the effec 
tiveness of the therapeutic intervention, preferably cortical 
stimulation, or to determine if an alternate intervention is 
indicated in the absence of treatment effect from a current 
therapeutic intervention. The comparisons could also be used 
to determine if further therapeutic intervention is indicated in 
the absence of any abnormal findings. The comparisons may 
further be used to modify cortical stimulation signal param 
eters, preferably AMPWM signal parameters, in accordance 
with the findings of the repeated quantitative assessment step. 
(O155 With specific reference to the BRT test method, 
repeat testing may include the application of one or more SS 
forms. The application of the one or more SS forms may be 
done in accordance with types and levels quantified for the 
same form of SS that was used or performed before therapeu 
tic intervention. 
0156 Further according to the method, BRT test method 
data may be acquired at a first location (e.g. a clinical loca 
tion) and the acquired BRT test method data transferred via 
electronic means to another location (e.g. a central analysis 
location) for the herein described analysis and statistical com 
parisons to be accomplished. The electronic means of data 
transfer may include, but isn't limited to means of data trans 
fer across a local area network and/or the internet. Conse 
quently, analysis and statistical findings may then be trans 
ferred from a central analysis location to a clinical location, 
where they may be used in various ways by a physician or 
similarly qualified health care professional for the determi 
nation of parameters of a cortical stimulation signal used for 
therapeutic intervention, treatment or alleviation of central 
ized pain. 
(O157. Further according to the method, BRT test method 
data may be acquired at a first location (e.g. a clinical loca 
tion) and the acquired BRT test method data transferred via 
electronic means to another location (e.g. a central analysis 
location) for a purpose such as inclusion or increasing the size 
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of various databases of individuals known to be suffering 
from centralized pain, individuals known to be suffering from 
pain that is not centralized pain, and healthy normal individu 
als. 
0158. Further according to the method, cortical stimula 
tion signal parameters may be determined at a central analysis 
location and Subsequently transferred as data via electronic 
means to an apparatus at another location (e.g. a clinical 
location) provided for delivery of a cortical stimulation signal 
used for therapeutic intervention, treatment or alleviation of 
centralized pain. The electronic means of data transfer may 
include, but isn't limited to, means of data transfer across a 
local area network and/or the internet. 
0159. The steps of application of the cortical stimulation 
signal and repeat measurements and analyses of a subjects 
BRT test method data may be continued until one or more 
abnormal brain conditions as determined by, for example, 
measures from further BRT test method analysis, are modu 
lated or alleviated, and/or alleviation of centralized pain is 
achieved. 
0160. Further according to the method, measures associ 
ated one or more brain conditions associated with centralized 
pain may be collected during a time period at or near the time 
of a therapeutic intervention Such as application of a cortical 
stimulation signal, and the measures may be analyzed by 
real-time computational algorithms to determine various 
measures and statistics associated with the brain conditions 
associated with centralized pain. The measures and statistics 
may then be used to modify parameters of an intervention for 
the purposes of optimizing therapeutic benefit. In a preferred 
embodiment, EEG data from one or more scalp locations are 
collected during a time period at or near the time of a thera 
peutic intervention Such as application of a cortical stimula 
tion signal, and an FFT is performed on the EEG data to 
determine various measures and statistics comprising spec 
tral parameters of the EEG data including, but not limited to, 
spectral amplitudes of said EEG data. In another preferred 
embodiment, EEG data from two or more scalp locations are 
analyzed to determine measures and statistics of brain net 
work connectivity associated with centralized pain. A com 
parison between any number of parameters of a cortical 
stimulation signal and the measures and statistics according 
to the embodiment can be made to determine a corresponding 
modification to the cortical stimulation signal’s parameters 
for the purpose of optimizing therapeutic benefit. 
0161 The application of a cortical stimulation signal is 
preferably accomplished with an AMPWM signal, and may 
comprise the steps of choosing AMPWM signal parameters 
intended to alleviate one or more abnormal brain conditions 
associated with centralized pain identified in accordance with 
the BRT test method, generating the AMPWM signal, and 
applying the AMPWM signal to a subject using any of the 
various apparatuses for AMPWM signal generation and 
delivery disclosed herein. Delivery of the AMPWM signal 
may be accomplished by utilizing an electrode set comprising 
one or more non-invasive stimulating electrodes adapted to be 
worn by a Subject, as also disclosed herein. 
0162. In addition, and as shown in FIG. 7, an apparatus 
200 for diagnosing and treating centralized pain may include 
a computer 201 interfaced to a signal generation and interface 
module 221 utilizing any number of methods known in the art 
such as the use of a computer interface cable 202. Any power 
source 203 known in the art to sufficiently provide power to 
computers and electronic devices may be utilized and exter 
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nally interfaced with power wires 204. The signal generation 
and interface module 221 may include a microcontroller 206 
electronically coupled to a signal generator circuit 207, to a 
biopotential acquisition circuit 208, Such as an EEG acquisi 
tion circuit, and to any number of device interface circuits 
209. All external interfaces may utilize connectors 205 com 
monly known in the art. All electrical and electronic coupling 
methods may utilize conductors 212 known in the art. 
0163. In practice, the computer 201 may be configured to 
communicate via interface 202 to the microcontroller 206 for 
various purposes including the transferofcortical stimulation 
signal parameters and the receipt of biopotential data. The 
computer 201 may include a user interface that allows an 
operator to monitor and/or influence operation of the appara 
tus 200 for diagnosing and treating centralized pain. 
0164. A cortical stimulation signal such as an AMPWM 
signal may be generated in the signal generator circuit 207 
and delivered to a stimulation signal interface 210 that 
includes connectors 205. As shown in FIG. 8, the signal 
generator circuit 207 may comprise a biopotential amplifier 
214. Such as a biopotential amplifier configured to measure 
EEG signals, and may be operatively coupled to any number 
of filter circuits 215 configured to reduce extraneous electri 
cal noise in a biopotential signal. The biopotential amplifier 
214 may be further operatively coupled to an isolation ampli 
fier 216 for human subject protection, and to a microcontrol 
ler 206 through an analog-to-digital interface 217. In opera 
tion, one or more biopotential signals may be acquired 
through a stimulation signal interface 210 comprising elec 
trical conductors 55 interfaced at connectors 205. The 
acquired biopotential signal may be conducted to a biopoten 
tial amplifier 214, filter circuits 215, isolation amplifier 216 
and to a microcontroller 206 foruse such as, but not limited to, 
in software executed by an interfaced computer 201 for gen 
erating and delivering a cortical stimulation signal. The signal 
generator circuit 207 may further comprise an isolated power 
supply 218 configured to provide circuit power and provide 
human Subject protection, a Switching transistor 219 that has 
base connection to a digital-to-analog interface 222 on a 
microcontroller 206, and an inductor 220 configured and 
positioned to induce an electrical stimulation signal Such as a 
cortical stimulation signal into a conductor 212 leading to a 
connector 205 in a stimulation signal interface 210. In opera 
tion, the microcontroller 206 may generate an electrical 
stimulation signal and conduct that signal via a digital-to 
analog interface 222 to the base of the Switching transistor 
219. Electrical power from an isolated power supply 218 may 
then switched on and off through the switching transistor 219 
creating an amplified Stimulation signal in accordance with 
the electrical stimulation signal waveform generated by the 
microcontroller 206. The amplified stimulation signal may be 
further conducted to an inductor 220, and further induced into 
a conductor 212 creating a cortical stimulation signal in the 
conductor 212. The cortical stimulation signal may then be 
delivered to a human subject via the conductor 212 to a 
cortical stimulation signal interface 210 comprising electrical 
conductors 55 interfaced at connectors 205. In other words, 
the cortical stimulation signal may be applied using an appa 
ratus comprising a microcontroller 206 configured to gener 
ate signal waveforms and coupled to a signal generator circuit 
207 configured to transform the signal waveforms into 
desired cortical stimulation signals. The signal generator cir 
cuit 207 may comprise circuit elements such as a biopotential 
amplifier 214 configured to measure biopotential signals, a 
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filter circuit 215 configured to reduce electrical noise in bio 
potential signals, an isolation amplifier 216 configured to 
protect human Subjects, an analog-to-digital interface 217 
configured to convert analog biopotential signals to digital 
signals, an isolated power Supply 218 configured to provide 
circuit power and human Subject protection, a Switching tran 
sistor 219 configured to generate an amplified stimulation 
signal by Switching on and off electrical power from the 
isolated power Supply in response to electrical stimulation 
signals received at a base of the Switching transistor from the 
microcontroller, and an inductor 220 configured to induce an 
amplified stimulation signal into a conductor 212. Additional 
forms of cortical stimulation signals such as an AMPWM 
signal and apparatus for generating an AMPWM signal are 
disclosed in the applicant's U.S. Pat. No. 7,715,910, which is 
attached as Appendix A. 
0.165. In addition, and further to a cap 3 configured to be 
worn on a Subject's head, an alternate embodiment of such a 
cap is shown at 33 in FIGS.9 and 10, which may be used with 
an abnormal brain function diagnostic and treatment appara 
tus 100 and/or an apparatus 200 for diagnosing and treating 
centralized pain. The cap 33 may include a series of intercon 
nectable flexible bands 20 configured to include arms 21 and 
tabs 22 that connect when placed on a head to form a means 
to fit the shape of the head. The flexible bands 20 may com 
prise Substrate materials further comprising electrical circuits 
23 and conductive pathways 24 integral to the Substrate mate 
rials. Further, the cap 33 may be adapted to carry any number 
of electrodes 1, 2, 30 for the purposes of both measuring one 
or more EEG signals and delivering one or more cortical 
stimulation signals to a subject for the purposes of assessing 
or alleviating abnormal brain measures associated with cen 
tralized pain, or altering network connectivity. 
0166 According to one embodiment, the cap 33 may com 
prise a series of interconnectable flexible bands 20 that may 
be made with materials designed to facilitate manufacturing 
for desired product variability. The materials may also be 
chosen to be inexpensive and disposable. 
0167. In one embodiment, the flexible bands 20 comprise 
electrically conductive pathways 24 leading to any number of 
electrodes 1, 2, 30 that may be integrated into the flexible 
bands 20. The electrodes 1, 2, 30 may be of any form suitable 
for either EEG measurement or conduction of a cortical 
stimulation signal, and may preferably be of a pre-prepared 
and pre-gelled form. The flexible bands 20 may further com 
prise areas of reusable self-adhesive material 28 to facilitate 
interconnection of the flexible bands 20 when placed on a 
head to form a cap 33 that beneficially fits the shape of the 
head. The flexible bands 20 may also comprise a series of 
markers 25 imprinted on various arms 21 and tabs 22, with the 
markers 25 individually conceived and located in ways to aid 
in proper connection and sizing to form a cap 33 on different 
sizes and shapes of a head. Further, the flexible bands 20 may 
also comprise a series of placement markers 26 imprinted on 
various arms 21 and tabs 22 to aid in proper placement of a 
cap 33 on a head. Further still, the electrically conductive 
pathways 24 in the flexible bands 20 may interface to electri 
cal conductors 55 that may electrically couple to connectors 
105 at a stimulation signal interface 110 and/or an EEG 
interface 111 of an abnormal brain function diagnostic and 
treatment apparatus 100 (FIG. 2 and 3); or to electrical con 
ductors 55 that electrically couple to connectors 205 at a 
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stimulation signal interface 210 and/or an EEG interface 211 
of an apparatus 200 for diagnosing and treating centralized 
pain (FIGS. 7 and 8). 
(0168 Further to the embodiment, the flexible bands 20 
may also comprise one or more electrical circuits 23 Such as 
integrated circuits configured to facilitate the measurement of 
one or more EEG signals or the delivery of one or more 
cortical stimulation signals, both to and from a head. 
Examples of such circuits may include, but are not limited to, 
signal conditioning circuits such as pre-amplifiers or filters, 
circuits for generating cortical stimulation signals, digital-to 
analog converters and analog-to-digital converters. 
(0169. Further to the embodiment, when interconnected 
the flexible bands 20 form a cap 33 that provides for electrode 
1, 2, 30 placement such that individual electrodes can be used 
for the purposes of either (1) measuring one or more EEG 
signals, (2) delivering one or more cortical stimulation sig 
nals to a subject, or (3) both measuring one or more EEG 
signals and delivering one or more cortical stimulation sig 
nals to a subject. Electrode placement may be consistent with 
a standard international 10-20 electrode positioning system 
for full EEG measurement, or a modified 10-20 electrode 
positioning system having fewer electrodes than the standard 
international 10-20 electrodepositioning system for localized 
or strategically limited EEG recordings. Alternately, the flex 
ible bands 20 may be configured to place one or more elec 
trodes 30 in locations that are not consistent with the standard 
international 10-20 electrodepositioning system. Alternately, 
the number of flexible bands 20 may be limited to only pro 
vide for placement and positioning of one or more electrodes 
1, 2, 30 in accordance with any positioning system, and there 
fore may not form a complete cap 33 when interconnected 
and placed on a head. 
(0170 Further to the embodiment, electrodes 1, 2, 30 posi 
tioned in flexible bands 20 may be configured to both provide 
for EEG measurement from a subject and conduction of a 
cortical stimulation signal to a subject at overlapping times. 
(0171 Further to the embodiment, the flexible bands 20 
may also comprise arms 21 and tabs 22 that position elec 
trodes 1, 2, 30 acting as ground electrodes to rest on the skin 
at non-EEG measurement sites Such as, but not limited to sites 
on one or both of a subject’s ears. 
0172 Further to the embodiment, the flexible bands 20, 
arms 21 or tabs 22 also comprise one or more electrical 
circuits 23 that further comprise one or more sensors 29 
configured to provide non-EEG measures. An example of one 
such embodiment includes arms 21, tabs 22, electrical cir 
cuits 23 and sensors 29 configured to measure an electroocu 
logram for purposes including, but not limited to measure 
ment of eye movements to aid in removal of non-EEG signals 
from an EEG record. Another example of an embodiment 
includes arms 21, tabs 22, electrical circuits 23 and sensors 29 
configured to measure electromyographic activity on or near 
ahead for purposes including, but not limited to measurement 
of muscle movements to aid in removal of non-EEG signals 
from an EEG record. Still another example of an embodiment 
includes arms 21, tabs 22, electrical circuits 23 and sensors 29 
Such as an accelerometer configured to measure physical 
motion of a subject for purposes including, but not limited to 
measurement of physical motion to aid in removal of non 
EEG signals from an EEG record. 
(0173. Further to the embodiment, electrodes 1, 2, 30 
including one or more ground electrodes may be positioned in 
flexible bands 20 for delivering one or more cortical stimula 
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tion signals to a subject. The combined positioning of elec 
trodes 1, 2, 30 may be arranged so that when the cap 33 is 
worn on a Subject's head in a predetermined orientation, a 
vector path extending between a stimulating electrode 1, 30 
and a ground electrode 2 passes through or proximate the 
desired area of brain tissues to be stimulated. 
0.174 As an alternate embodiment, a cap 33 may comprise 
any combination of a flexible material Such as cloth or paper 
configured to cover at least a portion of a head, flexible bands 
20 made of one or more materials that do not conduct elec 
tricity, and flexible bands 20 that do conduct electricity; all 
configured to provide alternate ways to accomplish the vari 
ous cap 33 embodiments disclosed herein. 
0175 Other embodiments of caps taught herein as being 
configured to be worn on a subject's head may be configured 
to carry any number of means known in the art for storing, 
transmitting or otherwise providing information. Such infor 
mation may include electronic data or means of accessing 
electronic data, and may further include, but is not limited to, 
a unique identification code that indicates what Subject the 
cap is intended or designated for use on, dates and times of 
use, parameters of a cortical stimulation signal to be used in 
association with the cap, the total number of times the cap has 
been used, and/or monitoring data associated with quality of 
use. Where it is desired that a cap be used only one time and 
Subsequently disposed, such information also includes means 
of indicating that the cap has been used, and/or information 
used by an abnormal brain function diagnostic and treatment 
apparatus 100 oran apparatus 200 for diagnosing and treating 
centralized pain to prevent the cap from being used again. 
0176). As previously disclosed, a cap 3 may be configured 
to carry any number of electrical circuits known in the art for 
storing information. As shown in FIG. 5. Such circuit may 
include a radio frequency identification (RFID) chip 7. As 
shown in FIG. 6, any number of programmable memory 
circuits 9 may be used as an alternative to the use of an RFID 
chip 7. Such methods may be practiced using any one of the 
disclosed cap embodiments. In a preferred embodiment, any 
one or more barcoding methods known in the art may be used 
for encoding and decoding data, whereby the barcode 27 may 
be inextricably integrated into any element of the cap 33. For 
example, a bar code 27 may be printed onto a flexible band 20 
of a cap 33. Further to this embodiment, an abnormal brain 
function diagnostic and treatment apparatus 100 or an appa 
ratus 200 for diagnosing and treating centralized pain may 
include a bar code reader (not shown) for which methods of 
use are also well-known in the art, and which may be used for 
accessing coded information stored in a bar code 27 on a cap 
33 in such away that the information incorporated into the bar 
code may be utilized by software executed by a microcon 
troller 106 and/or an interfaced computer 101 on an abnormal 
brain function diagnostic and treatment apparatus 100, or 
executed by a microcontroller 206 and/or an interfaced com 
puter 201 on the apparatus 200 for diagnosing and treating 
centralized pain. 
0177 Also provided is a means of preventing a cap from 
being used more than an allowed number of times, where the 
allowed number is preferably one. For example, this may be 
achieved by encoding a unique identification code for the cap 
33 into a bar code 27 integrated into an element of the cap 33. 
Alternately, a number of allowed uses may also be encoded 
into the caps bar code 27. Upon use of the cap 33, the user of 
an abnormal brain function diagnostic and treatment appara 
tus 100 or an apparatus 200 for diagnosing and treating cen 
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tralized pain, may use a bar code reader to access coded 
information stored on the bar code 27, including at least the 
unique identification code. Software executed by a microcon 
troller 106 and/or an interfaced computer 101 on an abnormal 
brain function diagnostic and treatment apparatus 100, or 
executed by a microcontroller 206 and/or an interfaced com 
puter 201 on an apparatus 200 for diagnosing and treating 
centralized pain, may compare the unique identification code 
against a database of unique identification codes of caps 33 
that have previously been used. If the number of previous uses 
stored in the database is less than the number of allowed uses, 
then the abnormal brain function diagnostic and treatment 
apparatus 100 or the apparatus 200 for diagnosing and treat 
ing centralized pain will permit the cap 33 to be used, that is, 
either apparatus 100, 200 will deliver a cortical stimulation 
signal to the cap 33. In this case, information about the caps 
use Such as the unique identification code will be added to a 
database of unique identification codes of caps 33. In the 
embodiment, the database may be stored locally on the appa 
ratus 100, 200, and/or it may be stored in a central location 
and accessed via network connection Such as the internet. If, 
on the other hand, the number of previous uses stored in the 
database is equal to the number of allowed uses, then the 
apparatus 100, 200 will not permit the cap 33 to be used, that 
is, the apparatus 100, 200 will not deliver a cortical stimula 
tion signal to the cap 33. 
0.178 The apparatus 200 for diagnosing and treating cen 
tralized pain may also include any number of external devices 
that may be utilized in the process of providing assessment, 
diagnostics, or therapy and that may be coupled to the device 
interface circuit 209 and interfaced through a device interface 
213 that may include connectors 205. For example, the appa 
ratus 200 may include a bar code reader for scanning a bar 
code 27 on a cap 33, or an RFID reader for reading informa 
tion on an RFID chip 7 on a cap 3. 
0179 Cortical stimulation may be used as a method of 
alleviating centralized pain in combination with treatment of 
other coexisting physical conditions that may or may not be 
associated with centralized pain. In addition, or alternatively, 
cortical stimulation may be used as a method of alleviating 
centralized pain in combination with other forms of treatment 
utilized to affect symptoms of centralized pain including, but 
not limited to, administering one or more pharmaceutical 
agents to the Subject to further augment alleviating central 
ized pain. 
0180 Referring to FIGS. 24-25, network connectivity in a 
Subject's brain may also be altered, e.g., may have its network 
connections increased or decreased in number or in strength, 
by applying brain stimulation to the Subject. The altering of 
network connectivity may be accomplished by administering 
a stimulation signal to tissues such that the stimulation signal 
is transmitted to one or more regions of the Subjects brain. 
These regions of the Subjects brain can include regions that 
are at least one part of a network to be altered; and can also 
include regions of the brain that are not part of a network to be 
altered, but are otherwise functionally interrelated with those 
regions that do possess such network. Accordingly, one of 
skill in the neurological arts would recognize which regions 
of the brain are functionally interrelated with other regions of 
the brain. 
0181. Where the method is directed toward altering net 
work connectivity in a subject, the method may include iden 
tifying at least one target network of the Subject's brain, 
identifying at least one target region of brain tissues that 
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either include or otherwise have network connections, such as 
functional network connections or effective network connec 
tions, that are functionally interrelated with the network to be 
altered, and stimulating the at least one target region of tissues 
to alter the network connections. The method may further 
include administering one or more pharmaceutical agents to 
the subject to influence the altering of one or more networks. 
0182. The stimulation of a target region of tissues to alter 
network connectivity in a brain can be accomplished in either 
an invasive or a noninvasive manner Such stimulation may 
include at least one administration of electrical stimulation to 
the target region of tissues of the Subject and may include at 
least one administration of magnetic stimulation to a target 
region of tissues. Stimulation may be administered in a non 
invasive manner in which stimulation is applied to a target 
region of tissues, such as tissues in the brain, from outside the 
Subject and transmitted through intervening tissues. 
0183 Electrical stimulation may include administration 
of a stimulating signal that is configured to minimize inter 
vening tissue impedance, Such as an AMPWM signal, to 
provide increased conduction of the stimulating signal 
through such tissues. The administration of an AMPWM 
signal may be accomplished by placing noninvasive cutane 
ous electrodes in an arrangement that allows for Successful 
delivery of the AMPWM stimulating signal to a target region 
of tissues of the Subject. This may be done using an apparatus 
configured to generate and deliver an AMPWM signal to the 
cutaneous electrodes, such as an apparatus 200 for diagnosing 
and treating centralized pain and a cap 33 configured to be 
worn on a Subject's head. 
0184. To determine the presence brain network connectiv 
ity to be altered, or the location of tissues to be stimulated, one 
skilled in the art of medical assessment may administer and 
interpret one or more tests designed to detect the presence 
and/or location of functional network connections and/or 
effective network connections. Such assessments may 
include any one or more known neuroimaging tests. Such 
assessments may also include a brain response test. 
0185. The administration of a pharmaceutical may include 
administering at least one pharmaceutical agent formulated to 
alter brain network connectivity. Further, the pharmaceutical 
administering step is preferably timed Such that the one or 
more pharmaceutical agents are present in the Subject during 
at least a portion of a time during which the stimulating step 
is executed. 
0186 The invention is not limited in any way to the 
embodiments disclosed herein. In this regard, no attempt is 
made to show structural details of the disclosed apparatuses 
or process details of the disclosed methods in more detail than 
is necessary for a fundamental understanding of the disclosed 
apparatuses and methods. The description is intended only to 
make apparent to those skilled in the art how the several forms 
of the invention may be embodied in practice. 
What is claimed is: 
1. A method for alleviating centralized pain, the method 
including the steps of 
assessing the brain of a subject suffering from pain; 
diagnosing one or more brain conditions associated with 
centralized pain; 
locating at least one area of abnormal brain measure asso 
ciated with an abnormal brain condition producing the 
centralized pain; and 
applying to tissues corresponding to the at least one area of 
abnormal brain measure a cortical stimulation signal 
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configured to alter the one or more brain conditions in 
Such a way as to alleviate the centralized pain. 
2. The method of claim 1 in which: 
the assessing step includes taking measures of a brain 
condition either by direct assessment techniques known 
in the art such as neuroimaging, or by indirect assess 
ment such as analysis of other biological measures; 
the diagnosing step includes making brain measures to 
Support a diagnosis of the presence of one or more brain 
conditions associated with centralized pain that is a 
result of central sensitivity; 
the locating step includes locating at least one area of 
abnormal brain measure associated with one or more 
brain conditions associated with centralized pain that is 
a result of central sensitivity; and 
the applying step includes applying a cortical stimulation 
signal configured to alter the one or more brain condi 
tions in Such away as to alleviate centralized pain that is 
a result of central sensitivity. 
3. The method of claim 1 in which: 
the diagnosing step includes determining abnormal brain 
measures to Supporta diagnosis of the presence of one or 
more brain conditions associated with centralized pain 
that is a result of abnormal network connectivity 
involved in pain processing: 
the locating step includes locating at least one area of 
abnormal brain measure associated with one or more 
brain conditions associated with centralized pain that is 
a result of abnormal network connectivity involved in 
pain processing; and 
the applying step includes applying a cortical stimulation 
signal configured to alter the one or more brain condi 
tions in Such away as to alleviate centralized pain that is 
a result of abnormal network connectivity involved in 
pain processing. 
4. The method of claim 1 in which the applying step 
includes applying a cortical stimulation signal that comprises 
waveforms configured to minimize tissue impedance. 
5. The method of claim 4 in which the applying step 
includes applying a cortical stimulation signal that comprises 
an AMPWM signal. 
6. The method claim 1 in which: 
the assessing step includes taking measures to determine 
the presence of a brain condition associated with cen 
tralized pain; 
the diagnosing step includes making a determination of a 
brain condition associated with centralized pain; and 
the locating step includes identifying at least one target 
region of the subject’s brain where a brain condition 
involved in producing centralized pain originates. 
7. The method of claim 6 in which the assessing step 
includes making brain measures using one or more neuroim 
aging tests directed toward determining the presence of cen 
tralized pain. 
8. A method of assessing a brain to determine the presence 
of centralized pain, the method including the use of a brain 
response test (BRT) comprising one or more neuroimaging 
tests performed before, during and after the application of any 
one or more sensory stimulations to cause one or more brain 
responses. 
9. The method of claim 8 in which the sensory stimulations 
include noxious, pain inducing or non-painful means of caus 
ing one or more brain responses. 
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10. The method of claim 8 in which a neuroimaging test 
includes an electroencephalogram (EEG) test. 
11. The method of claim 9 in which sensory stimulations 
are selected from the group of sensory stimulations consisting 
of a tender point test, application of mechanical pressure on 
any part of the body, application of otherforms of mechanical 
stimulation to any part of the body, application of an electrical 
stimulus, application of a heat-producing stimulus, in vivo or 
in vitro introduction of a chemical agent, mechanical brush 
ing, controlled physical movements made by the Subject, or 
forms of mental processing Such as cognitive exercises. 
12. The method of claim 8 in which a series of sensory 
stimulations are made over a period of time in Such a way as 
to produce multiple brain responses. 
13. The method of claim 12 in which a BRT includes 
assessing changes in brain response over a period of time. 
14. The method of claim 10 in which EEG data is obtained 
for a period of time before, during, and after the application of 
any number of one or more sensory stimulations. 
15. The method of claim 14 in which the EEG data is 
obtained overa period of time of approximately one second to 
15 minutes before application of a sensory stimulation. 
16. The method of claim 8 in which a record of a BRT test 
includes quantifying parameters associated with the one or 
more sensory stimulations. 
17. The method of claim 16 in which recording of quanti 
fied parameters occurs at or near the time the Subject reports 
a painful sensation. 
18. The method of claim 16 in which parameters are 
selected from a group of parameters consisting of location of 
mechanical pressure, amount of mechanical pressure, param 
eters of other forms of mechanical stimuli, parameters of 
forms of electrical stimuli, parameters of forms of heat 
stimuli, parameters of an introduced chemical agent, param 
eters of brush strokes, or parameters of a mental exercise. 
19. The method of claim 14 in which the recording of EEG 
continues for a period of time after application of each of the 
one more sensory stimulation applications. 
20. The method of claim 19 in which the period of time is 
between one second and 15 minutes. 
21. The method of claim 19 in which the step of recording 
EEG includes producing a resulting EEG data record that 
includes the brain response test EEG records following each 
one or more applications of one or more sensory stimulations. 
22. The method of claim 21 in which EEG data that have 
minimal non-EEG signals are extracted from each EEG 
record to provide a period of clean EEG data sufficient to 
perform an EEG analysis. 
23. The method of claim 22 in which the step of extracting 
from each EEG record includes obtaining clean EEG data that 
have minimal non-EEG signals and do not include any EEG 
data acquired during the application of any one or more 
sensory stimulations. 
24. The method of claim 23, in which clean EEG records 
are mathematically analyzed. 
25. The method of claim 24, in which EEG records are 
mathematically analyzed by selecting one or more analyses 
from a group consisting of time domain and frequency 
domain parameters. 
26. The method of claim 25, in which EEG records are 
mathematically analyzed by selecting one or more analyses 
from a group consisting of Voltage analysis, current analysis, 
Voltage and current analysis, frequency spectrum analysis 
using Fast Fourier Transform (FFT) analysis, frequency spec 
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trum analysis using a wavelet analysis method, frequency 
spectrum analysis using absolute power analysis method, 
frequency spectrum analysis using relative power analysis 
method, frequency spectrum analysis using phase analysis 
method, frequency spectrum analysis using coherence analy 
sis method, frequency spectrum analysis using amplitude 
symmetry analysis method, phase analysis, various forms of 
network analysis and source localization of electrical activity 
in the brain using inverse EEG computation analysis. 
27. The method of claim 24 in which mathematical analy 
sis is used to determine one or more brain measures to Support 
a diagnosis of the presence of one or more brain conditions 
associated with centralized pain. 
28. The method of claim8, in which a finding of centralized 
pain is made by analyzing findings from one or more BRT 
testS. 
29. The method of claim 28, in which analyzing findings 
from one or more BRT tests includes performing one or more 
analyses to discover one or more brain conditions associated 
with central sensitivity or abnormal brain network connectiv 
ity associated with pain processing. 
30. The method of claim 28, in which BRT EEG records are 
statistically compared to EEG records taken from either 
healthy normal individuals or individuals that are suffering 
from pain that is not centralized pain. 
31. The method of claim 24 in which EEG abnormalities 
consistent with Subjects Suffering from centralized pain are 
selected from the group of abnormalities consisting of abnor 
mal levels of EEG power, abnormal levels of coherence 
between at least two EEG sites, abnormal levels of phase shift 
between at least two EEG sites, or abnormal levels of EEG 
relative power in particular regions of the brain. 
32. The method of claim 8, in which determination of 
centralized pain includes physical assessment augmented by 
assessment of a brain following a BRT. 
33. The method of claim 28, in which assessment of a BRT 
includes a statistical comparison between any one or more of 
the subjects BRT measures and a database of like BRT mea 
sures of either healthy normal individuals, individuals suffer 
ing from pain that is not centralized pain, or individuals 
Suffering from centralized pain. 
34. The method of claim 28, in which centralized pain is 
diagnosed by statistically determining one or more deviations 
between a subjects one or more BRT measures and like BRT 
measures obtained from at least one healthy normal indi 
vidual or at least one individual Suffering from pain that is not 
centralized pain; then comparing the one or more deviations 
to like deviations detected in a sample population of Subjects 
known to be suffering from centralized pain. 
35. The method of claim 34, in which a finding of central 
ized pain is made when findings of a comparison of param 
eters in a BRT test are statistically different from like param 
eters in a database of healthy normal individuals, individuals 
Suffering from pain that is not centralized pain; or statistically 
equivalent to like parameters in a database of individuals 
known to be suffering from centralized pain. 
36. A method of predicting symptom severity in individu 
als having centralized pain, the method including the steps of 
executing BRT testing on a Subject; 
obtaining brain measures associated with centralized pain 
in the subject by analyzing findings from the BRT test 
ing; and 
correlating the brain measures to measures of symptom 
severity. 
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37. A method of determining the effect of therapeutic inter 
vention in alleviating symptoms of centralized pain, the 
method including the steps of 
executing BRT testing on a subject; 
obtaining brain measures associated with centralized pain 
in the subject by analyzing findings from the BRT test 
ing; and 
correlating the brain measures to measures of the effect of 
therapeutic intervention. 
38. A method for determining points for application of 
cortical stimulation for alleviating centralized pain by ana 
lyzing a BRT. 
39. The method of claim 1, in which the diagnosing one or 
more brain conditions associated with centralized pain step 
includes determining that at least one abnormal measure of 
the Subject's brain associated with centralized pain corre 
sponds to at least one statistically significant difference find 
ing of a BRT test method. 
40. The method of claim 39, further comprising the steps 
of: 
repeating one or more analyses in accordance with the BRT 
test method following a period of therapeutic interven 
tion on said Subject; 
making a statistical comparison of parameters of the 
repeated analyses to like parameters of the analyses of 
the subjects BRT measures done before the period of 
therapeutic intervention was started; 
using these comparisons to assess the effectiveness of the 
therapeutic intervention, or to determine if an alternate 
intervention is indicated in the absence of treatment 
effect from a current therapeutic intervention; 
using these comparisons to determine if further therapeutic 
intervention is indicated in the absence of any abnormal 
findings; and 
using these comparisons to modify cortical stimulation 
signal parameters. 
41. The method of claim 40, in which repeating one or 
more analyses in accordance with the BRT test method 
includes application of one or more sensory stimulation 
forms. 
42. The method of claim 41, in which the one or more 
sensory stimulations are of types and levels used or per 
formed before therapeutic intervention. 
43. The method of claim 28, in which BRT test method data 
is acquired at a first location and the acquired BRT test 
method data is transferred via electronic means to a second 
location for analysis and statistical comparison. 
44. The method of claim 43, in which BRT test method 
analysis and statistical comparison findings are transferred 
via electronic means from a second location to a first location. 
45. The method of claim 44, in which electronic means of 
data transfer includes data transfer across a local area network 
and/or the internet. 
46. The method of claim 44, in which BRT test method data 
is transferred via electronic means to be included in or to 
increase the size of databases of individuals known to be 
Suffering from centralized pain, individuals known to be suf 
fering from pain that is not centralized pain, and healthy 
normal individuals. 
47. The method of claim 44, in which cortical stimulation 
signal parameters are determined at a second location and 
Subsequently transferred as data via electronic means to an 
apparatus at a first location. 
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48. The method of claim 40, in which the steps of applica 
tion of a cortical stimulation signal and repeat measurements 
and analyses of a subject's BRT test method data are contin 
ued until one or more abnormal brain conditions are modu 
lated or alleviated, and/or alleviation of centralized pain is 
achieved. 
49. A method for optimizing an intervention for alleviating 
centralized pain, the method including the steps of 
collecting brain measures associated with one or more 
abnormal brain conditions associated with centralized 
pain during a time period at or near the time of a thera 
peutic intervention; 
analyzing the brain measures by computational algorithms 
to determine measures and statistics associated with the 
brain measures; and 
using the measures and statistics to modify parameters of 
an intervention for the purposes of optimizing therapeu 
tic benefit. 
50. The method of claim 49, in which: 
the collecting step includes collecting brain measures asso 
ciated with one or more abnormalbrain conditions asso 
ciated with centralized pain during an intervention that 
includes application of a cortical stimulation signal; and 
the using step includes using the measures and Statistics to 
modify parameters of the cortical stimulation signal. 
51. The method of claim 49, in which: 
the collecting step includes collecting data from a BRT test 
comprising an EEG test; 
the step of analyzing data includes determining measures and 
statistics of EEG data; and 
the using step includes using measures and Statistics of the 
EEG data. 
52. The method of claim 49, in which: 
the collecting step includes collecting data from a BRT test 
comprising an EEG test; and 
the step of analyzing data includes analyzing EEG data 
from two or more scalp locations to determine measures 
and statistics of brain network connectivity associated 
with centralized pain. 
53. The method of claim 49, in which a comparison 
between one or more parameters of a cortical stimulation 
signal and one or more measures and statistics is made in Such 
a way as to determine a corresponding modification to the 
cortical stimulation signal’s parameters for the purpose of 
optimizing therapeutic benefit. 
54. The method of claim 1 in which the cortical stimulation 
signal is applied using an apparatus comprising a microcon 
troller configured to generate signal waveforms and coupled 
to a signal generator circuit configured to transform the signal 
waveforms into desired stimulation signals and comprising 
any one or more circuit elements selected from the group of 
circuit elements consisting of a biopotential amplifier config 
ured to measure biopotential signals, a filter circuit config 
ured to reduce electrical noise in biopotential signals, an 
isolation amplifier configured to protect human Subjects, an 
analog-to-digital interface configured to convert analog bio 
potential signals to digital signals, an isolated power Supply 
configured to provide circuit power and human Subject pro 
tection, a Switching transistor configured to generate an 
amplified stimulation signal by Switching on and off electri 
cal power from the isolated power Supply in response to 
stimulation signals received at a base of the Switching tran 
sistor from the microcontroller, and an inductor configured to 
induce a cortical stimulation signal into a conductor. 
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55. An apparatus for providing a stimulation signal, the 
apparatus comprising a cap configured to be worn on a Sub 
jects head, and further comprising a series of interconnect 
able flexible bands configured to include arms and tabs that 
connect when placedon ahead to form a means to fit the shape 
of the head. 
56. The apparatus of claim 55, in which the flexible bands 
comprise Substrate materials further comprising circuits and 
conductive pathways integral to the Substrate materials. 
57. The apparatus of claim 55, in which the cap is adapted 
to carry one or more electrodes configured to both measure 
one or more EEG signals and to deliver one or more cortical 
stimulation signals to a Subject. 
58. The apparatus of claim 57, in which the one or more 
electrodes are configured to both measure one or more EEG 
signals and to deliver one or more cortical stimulation signals 
to a subject in Such away as to assess or alleviate one or more 
abnormal brain conditions associated with centralized pain. 
59. The apparatus of claim 57, in which the flexible bands 
comprise electrically conductive pathways leading to the one 
or more electrodes integrated into the flexible bands. 
60. The apparatus of claim 57, in which the electrodes are 
configured for either EEG measurement or conduction of a 
cortical stimulation signal. 
61. The apparatus of claim 60, in which the electrodes are 
pre-prepared and pre-gelled. 
62. The apparatus of claim 55, in which the flexible bands 
further comprise areas of reusable self-adhesive material con 
figured to facilitate interconnection of the flexible bands 
when placed on a head to form a cap. 
63. The apparatus of claim 55, in which the flexible bands 
further comprise one or more markers that are imprinted on 
arms or tabs and that are located so as to aid in properarm and 
tab connection and sizing to form a cap on different sizes and 
shapes of a head. 
64. The apparatus of claim 55, in which the flexible bands 
further comprise one or more markers that are imprinted on 
arms or tabs and that are located so as to aid in proper place 
ment of a cap on a head. 
65. The apparatus of claim 59, in which the electrically 
conductive pathways in the flexible bands interface to elec 
trical conductors that electrically couple to connectors at a 
stimulation signal interface and/or an EEG interface. 
66. The apparatus of claim 55, in which the flexible bands 
further comprise one or more electrical circuits configured to 
facilitate the measurement of one or more EEG signals or the 
delivery of one or more cortical stimulation signals. 
67. An apparatus for diagnosing and treating centralized 
pain, the apparatus comprising a cap configured to be worn on 
a Subject's head, and further comprising interconnected flex 
ible bands that form the cap and that are configured to position 
one or more electrodes to measure one or more EEG signals 
from a subject and/or deliver one or more cortical stimulation 
signals to a Subject. 
68. The apparatus of claim 67, in which the bands are 
configured to position the one or more electrodes consistent 
with a standard international 10-20 electrode positioning sys 
tem for EEG measurement. 
69. The apparatus of claim 67, in which the bands are 
configured to position the one or more electrodes consistent 
with a modified international 10-20 electrode positioning 
system having fewer electrodes than the standard interna 
tional 10-20 electrode positioning system for localized or 
strategically limited EEG recordings. 
20 
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70. The apparatus of claim 67, in which the flexible bands 
are configured to position the one or more electrodes in 
respective locations that are not consistent with the standard 
international 10-20 electrode positioning system. 
71. The apparatus of claim 57, in which individual elec 
trodes positioned in flexible bands are configured to both 
provide for EEG measurement from a subject and conduct a 
cortical stimulation signal to a subject. 
72. The apparatus of claim 57, in which the flexible bands 
comprise arms and tabs configured to position one or more 
electrodes in Such a way as to rest on a Subject's skin at 
non-EEG measurement sites and act as ground electrodes. 
73. The apparatus of claim 72, in which the flexible bands 
comprise arms and tabs configured to position one or more 
electrodes in Such a way as to rest on non-EEG measurement 
sites. 
74. The apparatus of claim 57, in which the flexible bands 
comprise arms or tabs that further comprise one or more 
electrical circuits and one or more sensors configured to pro 
vide non-EEG measures. 
75. The apparatus of claim 74, in which the one or more 
non-EEG measures are selected from the group of measures 
consisting of an electrooculogram, electromyographic activ 
ity, or measures of physical motion of a Subject. 
76. A method for delivering one or more cortical stimula 
tion signals to a subject, the method including the use of an 
apparatus comprising one or more electrodes including one or 
more ground electrodes positioned in flexible bands config 
ured to include arms and tabs that connect when placed on a 
head to form a cap and means to fit the shape of the head. 
77. The method of claim 76, in which the apparatus further 
comprises positioning of electrodes Such that, when the cap is 
worn on a Subject's head in a predetermined orientation, a 
vector path extending between the stimulating electrode and 
the ground electrode passes through or proximate a desired 
area of brain tissues to be stimulated. 
78. The apparatus of claim 55, in which the cap comprises 
flexible material configured to cover at least a portion of a 
head, at least one flexible band comprising one or more mate 
rials that do not conduct electricity, and at least one flexible 
band comprising at least one material that does conduct elec 
tricity. 
79. An abnormal brain function diagnostic and treatment 
apparatus comprising a cap configured to be worn on a Sub 
jects head and comprising one or more electrodes positioned 
to contact a Subjects head when the Subject is wearing the 
cap, and the cap further comprising a memory configured to 
store information. 
80. The apparatus of claim 79, in which the cap comprises 
a transmitter connected to the memory and configured to 
transmit or otherwise provide the stored information to a 
receiver. 
81. The apparatus of claim 79, in which the cap is config 
ured to store/transmit information comprising one or more 
forms of information selected from the group of information 
forms consisting of a unique identification code for the cap, 
the identification of the subject the cap is intended to be used 
on, dates and times of use, parameters of a cortical stimulation 
signal to be used with the cap, the total number of times the 
cap has been used, or monitoring data associated with quality 
of use. 
82. The apparatus of claim 79, in which the cap is config 
ured to store/transmit information that includes an indication 
as to whether or not the cap has been used. 
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83. The apparatus of claim 82, in which the cap is config 
ured to store/transmit information usable to prevent the cap 
from being used again. 
84. The apparatus of claim 80, in which means for storing, 
transmitting or otherwise providing information includes one 
or more bar coding methods for encoding and decoding data, 
and where the bar code is integrated into an element of the 
Cap. 
85. The apparatus of claim 79, in which the abnormal brain 
function treatment apparatus further comprises a bar code 
reader configured to access information stored in a bar code 
On a cap. 
86. The apparatus of claim 55, further comprising a bar 
code reader configured to access information stored in a bar 
code on a cap. 
87. A method of preventing a cap from being used more 
than a predetermined number of times, the method including: 
providing a cap identifier on the cap; 
providing on the cap an allowed use indicator representing 
a predetermined number of allowed uses for the cap: 
gaining access to stored information in the cap identifier 
and the cap allowed use indicator; 
comparing the stored information against a database of 
information on caps that have previously been used; 
comparing the number of allowed uses indicated in the cap 
allowed use indicator against the previous cap use num 
ber stored in the cap information database; and 
configuring an apparatus for diagnosing and treating cen 
tralized pain to allow use of the cap only if the cap 
information database indicates that the previous cap use 
number is less than the number of allowed uses indicated 
by the cap allowed use indicator. 
88. The method of claim 87 in which the cap identifier and 
cap allowed use indicator comprise information storage 
devices selected from the group of storage devices consisting 
of a bar code or an RFID chip. 
89. The method of claim 87 in which information in the cap 
identifier and cap allowed use indicator is accessed using a 
reader selected from the group of readers consisting of a bar 
code reader oran RFID chip reader. 
90. The method of claim 87, in which information about a 
caps use is added to the cap information database upon use of 
the cap. 
91. The method of claim 90, in which the cap information 
database is stored locally on an apparatus for diagnosing and 
treating centralized pain. 
92. The method of claim 90, in which the cap information 
database is stored in a central location and accessed via a 
network connection. 
93. The method of claim 1, in which cortical stimulation is 
used to alleviate centralized pain in combination with treat 
ment of at least one other coexisting physical condition. 
94. The method of claim 1, in which cortical stimulation is 
used to alleviate centralized pain in combination with at least 
one other form of treatment utilized to affect symptoms of 
centralized pain. 
95. The method of claim 94, in which at least one other 
form of treatment utilized to affect symptoms of centralized 
pain includes administering one or more pharmaceutical 
agents to the Subject. 
96. A method for altering brain network connectivity in a 
Subject, the method including the steps of: 
identifying at least one target network of the Subjects 
brain; 
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identifying at least one target region of tissues that has 
network connections functionally interrelated with the 
at least one target network; and 
altering network connectivity in the at least one target 
network by stimulating the at least one target region of 
tissues. 
97. The method of claim 96 wherein the step of identifying 
at least one target region of tissues includes identifying a 
target region of tissues including brain tissues that comprise 
at least one part of a network to be altered. 
98. The method of claim 96, wherein the identifying steps 
include the administration of one or more tests designed to 
detect the presence and location of one or more network 
connections. 
99. The method of claim 96 wherein the step of altering 
network connectivity includes altering functional network 
connectivity. 
100. The method of claim 96 wherein the step of altering 
network connectivity includes altering effective network con 
nectivity. 
101. The method of claim 96, wherein the stimulating step 
includes at least one administration of electrical stimulation 
to the at least one target region of tissues. 
102. The method of claim 96, wherein the stimulating step 
includes at least one administration of magnetic stimulation 
to the at least one target region of tissues. 
103. The method of claim 96, wherein the stimulating step 
is performed in a noninvasive manner. 
104. The method of claim 103, wherein the noninvasive 
manner includes stimulation applied to a target region of 
tissues from outside the Subject and transmitted through inter 
vening tissues. 
105. The method of claim 96, wherein the stimulating step 
is performed in an invasive manner. 
106. The method of claim 101, wherein the step of admin 
istering electrical stimulation includes administration of an 
AMPWM signal. 
107. The method of claim 96, wherein the step of altering 
network connectivity includes stimulating the at least one 
target region of tissues such that network connectivity is 
increased. 
108. The method of claim 96, wherein the step of altering 
network connectivity includes stimulating the at least one 
target region of tissues such that network connectivity is 
decreased. 
109. The method of claim 101, in which the stimulation is 
applied using an apparatus comprising a microcontroller con 
figured to generate signal waveforms and coupled to a signal 
generator circuit configured to transform the signal wave 
forms into desired stimulation signals and comprising any 
one or more circuit elements selected from the group of 
circuit elements consisting of a biopotential amplifier config 
ured to measure biopotential signals, a filter circuit config 
ured to reduce electrical noise in biopotential signals, an 
isolation amplifier configured to protect human Subjects, an 
analog-to-digital interface configured to convert analog bio 
potential signals to digital signals, an isolated power Supply 
configured to provide circuit power and human Subject pro 
tection, a Switching transistor configured to generate an 
amplified stimulation signal by Switching on and off electri 
cal power from the isolated power Supply in response to 
stimulation signals received at a base of the Switching tran 
sistor from the microcontroller, and an inductor configured to 
induce a stimulation signal into a conductor. 
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110. The method of claim 96, wherein altering brain net 
work connectivity includes administering one or more phar 
maceutical agents to the Subject. 
111. The method of claim 98, wherein the administration of 
one or more tests steps includes at least one neuroimaging 
teSt. 
112. The method of claim 98, wherein the administration of 
one or more tests steps includes at least one brain response 
teSt. 
113. The apparatus of claim 57, in which the one or more 
electrodes are configured to measure one or more EEG sig 
nals and to deliver one or more cortical stimulation signals to 
a subject in Such a way as to alter network connectivity. 
114. An apparatus for altering network connectivity, the 
apparatus comprising a cap configured to be worn on a Sub 
jects head, and further comprising interconnected flexible 
bands that are configured to position one or more electrodes to 
22 
May 21, 2015 
measure one or more EEG signals from a Subject and/or 
deliver one or more cortical stimulation signals to a Subject. 
115. The apparatus of claim 114, in which the bands are 
configured to position the one or more electrodes consistent 
with a standard international 10-20 electrode positioning sys 
tem for EEG measurement. 
116. The apparatus of claim 114, in which the bands are 
configured to position the one or more electrodes consistent 
with a modified international 10-20 electrode positioning 
system having fewer electrodes than the standard interna 
tional 10-20 electrode positioning system for localized or 
strategically limited EEG recordings. 
117. The apparatus of claim 114, in which the flexible 
bands are configured to position the one or more electrodes in 
respective locations that are not consistent with the standard 
international 10-20 electrode positioning system. 
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